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ABSTRACT 
This project explored a gene-regulated chemotherapy using a silver nanoparticle 
(SNP) conjugated with deoxyribozyme (DNAzyme) oligonucleotides which target a 
mutated gene in select cancer cells, sensitize them to doxorubicin treatment.  Light 
exposure to the SNP-DNAzyme conjugates disengages the oligonucleotides and permits 
specific cleavage of the Kirsten Rat Sarcomal Oncogene Homolog (K-RAS) mRNA.  
These conjugates could provide spatiotemporal specificity in killing only those 
photoexposed cells with the mutant gene.  Synthesis, functionalization and 
characterization of citrate and hydroxypropyl cellulose SNP conjugates confirmed 
attachment and photolytic release of the thiol-modified 10-23 DNAzyme.  Gel 
electrophoresis was used to demonstrate DNAzyme photoactivation, showing greater K-
RAS RNA degradation when disengaged compared to the SNP-tethered form.  
DNAzyme in the tethered form was also protected from DNAse degradation compared to 
photolyzed DNAzyme.  Characterization of the toxicity and localization of the 
nanoparticle drug delivery system constructed for the release of a photolabile DNA 
oligonucleotide was checked within several sets of cells to check for temporal and spatial 
control efficiency.  MTS, alamar blue, and flow cytometry assays were performed to 
assess cell viability in several sets of cell cultures, including HEK293 and MCF-7 
(wildtype K-RAS),  SW480 and MDA-MB-231 (mutant K-RAS), and 3T3 (negative 
control) lines.  Following the 5-day experimental protocol involving staggered treatment 
with SNP-DNAzyme, UV light, and doxorubicin, no cell group showed the intended 
pattern of necrosis in mutant K-RAS cells without morbidity in controls or partial 
treatments.  Thus further evaluation of K-RAS+/- cells which respond consistently in 
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viability assays is necessary before this strategy can be deemed of potential as a targeted 
therapeutic. 
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CHAPTER 1. SIGNIFICANCE AND BACKGROUND 
1.1 OBJECTIVES 
This project has proposes a nanoscale oligonucleotide delivery system that is designed to 
overcome some known hurdles in chemotherapeutic applications.  Because some reports have 
shown that K-RAS mutations in colon and breast cancer cells increase their survival, this 
approach seeks to disrupt the mutant gene in targeted cells and sensitize them to doxorubicin, a 
standard chemotherapeutic.   K-RAS mRNA is cleaved by a specific deoxyribozyme 
(DNAzyme) oligonucleotide tethered with a photolabile linker to a silver nanoparticle (SNP) 
which facilitates protection from nucleases as well as cellular delivery.  
Nanoparticle conjugate synthesis, functionalization, and characterization were performed 
on the SNP-DNAzyme constructs along with their evaluation in cell cultures as models for 
targeted killing of cancer cells, as shown in Figure 1.1.  SNP-DNAzyme conjugates were 
constructed using a citrate-based SNP synthesis approach as well as with hydroxypropylcellulose 
(HPC SNPs) as starting materials.  Kirsten rat sarcoma viral oncogene homolog (KRAS) genes 
were evaluated for cleavage by KRAS DNAzymes in standard deoxyribonucleotide and 
modified oligonucleotide forms.  Staggered delivery of SNP-DNAzyme and Doxorubicin in 
SW620 KRAS mutant colon cancer cell lines was evaluated.  Staggered delivery of SNP-
DNAzyme and Doxorubicin within SW480 KRAS mutant colon cancer cell lines and MDA-MB-
231 KRAS mutant breast cancer cells were also are characterized as an alternative method. 
1.2 SIGNIFICANCE: THE CLINICAL NEED  
 In addition to traditional pharmacological agents, some treatments utilize internal 
machinery already present in cells to produce the desired therapeutic effect.  At present, a 
number of methods are well characterized for acting on the mRNA level by preventing protein 
2 
 
expression.  Specifically, these methods can be used to inhibit production of diseases in which 
gene silencing is critical (reviewed by (Bianco and Robey 2001)).  These therapeutic techniques 
make use of deoxyribozymes (DNAzyme), microRNAs (miRNA), and antisense 
oligonucleotides (reviewed by (Kurreck 2003)).  DNAzymes are RNA-cleaving DNA 
oligonucleotides with enzyme characteristics (Santoro and Joyce 1998). miRNAs are 
endogenous single-stranded RNAs approximately 22 nucleotides long that utilize the RNA 
interference (RNAi) pathway’s machinery, which cleaves the miRNA’s complementary target 
(reviewed by (Lingel and Sattler 2005)).  Antisense oligonucleotides are strands of 15 to 20 
nucleotides long that hybridize to their intended target mRNA and block translation (reviewed by 
(Dias and Stein 2002)). The basic premise of this project is to design and test a DNAzyme-
functionalized nanoparticle whose attachment site is photocleavable to achieve temporal and 
spatial control of the oligonucleotide drug release.  Temporal and spatial control addresses one of 
the main problems for reduction of incorrect targeting, thus reducing secondary symptomatic 
problems. 
 
Figure 1.1. Objectives for the project.  
Design, Construct,  and 
Characterize SNP-
DNAzyme 
•UV/Vis scan  
•TEM 
•ICPOES 
•DLS 
•Zeta potential 
Evaluate Cleavage of K-
RAS using DNAzyme 
and SNP-DNAzyme 
•Native and Denaturing 
electrophoresis gel 
•Image J characterization of 
pixel intensity  
Characterize Cell 
Response to SNP-
DNAzyme and 
Doxorubicin 
•MTS assay 
•Alamar Blue assay 
•Flow Cytometry assay 
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 Some oligonucleotide drugs are used in clinical trials while others are in the earliest stage 
of development (reviewed by (Akkina, Banerjea et al.)).  The use of DNAzymes, antisense 
oligonucleotides, and the RNA interference pathway are the most explored techniques at present.  
Figure 1.2 illustrates the mechanism of action for all three of these techniques.  Although their 
end results all include the prevention of protein expression, their pathways utilize separate 
machinery (reviewed by (Kurreck 2003)). Antisense oligonucleotides stop translation of their 
intended target by blocking the complementary sequence or by cleaving the complement using 
RNAse H.  DNAzymes cleave their targeted complementary sequence.   
  
 
 
 
 
 
 
 
Figure 1.2. Antisense oligonucleotide and DNAzyme pathways(Kurreck 2003). 
            Antisense oligonucleotides and DNAzymes use  distinct internal machinery, thus specific 
cleavage of mRNA is performed.  However, common problems persist for the therapeutic 
applications using these systems.  The problems to improve include protecting the gene silencing 
oligonucleotides from degradation by enzymes and achieving cellular uptake (reviewed by 
(Kurreck 2003)). The carriers utilized in this project, silver nanoparticles (SNPs), are used to 
address the protection of the gene silencing oligonucleotides by blocking the attachment of 
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endonucleases.  SNPs have also shown promise in delivering oligonucleotides 
intracellularly(Brown, Qureshi et al. 2013).  The SNPs will be functionalized with a 10-23 
DNAzyme that has demonstrated cleavage of RNA.  In addition to the SNP and DNAzyme being 
joined by a thiol bond, the DNA construct includes a photocleavable nitrobenzyl linker to control 
oligonucleotide release from the SNP.  The SNP-DNAzyme construct is designed to work in a 
system requiring targeted gene silencing.   
 KRAS DNAzymes actively cut the corresponding KRAS mRNA.  miRNA125b 
DNAzymes were originally used for a breast cancer treatment.  Cleavage of the miRNA 125b’s 
complement was unsuccessful, thus the project changed to cells with the KRAS mutation.  Some 
populations of colon cancer and breast cancer cells benefit from the mutation of the KRAS gene.  
KRAS translationally produces a mutated GTPase protein causing abnormal tissue signaling, 
accordingly increasing the formation of tumors.  SW620 and SW480 colon cancer cell lines have 
the KRAS mutation in codon 12 from the nucleotide exchange from a glycine to a valine 
codon(Yu, Wang et al. 2009).  MDA-MB-231 breast cancer cell lines have the KRAS mutation 
in codon 13 from the nucleotide exchange from a glycine to an aspartic acid codon(Hollestelle, 
Elstrodt et al. 2007). Figure 1.3 displays the overall goal of this project; the focal point is on a 
gene-regulated chemotherapy system using the staggered delivery of SNP-DNAzyme and 
doxorubicin to improve targeted killing of colon and breast cancer cells. 
In summary, this project has significance because it proposes a drug delivery system that 
is designed to overcome some known hurdles in therapeutic applications.  More specifically, the 
project addresses the method in which colon and breast cancer cells survive by taking advantage 
of a mutated gene important in normal cell signaling;  the mutated mRNA is cleaved using a 
functionalized nanoparticle with a photocleavable oligonucleotide, and a well-known 
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chemotherapeutic agent, doxorubicin.  This system is novel because it allows for temporal and 
spatial control of the oligonucleotide release and may lead to a reduction of the dosage of 
doxorubicin drug needed due to the actions of the DNAzyme. 
    
Figure 1.3. Aims of project include gene regulated chemotherapy using nanoscale DNA 
conjugates. 
 
1.3 10-23 DNAZYME FOR GENE SILENCING  
In 1980, Cech et al. found that certain RNA molecules, now termed ribozymes, catalyze 
reactions without any help from proteins (Cech, Zaug et al. 1981).  Subsequently, several 
catalytically active nucleic acids have been found to cleave RNA.  Ribozymes and DNAzymes 
are nucleic acid oligonucleotides that catalytically cleave RNAs with great specificity (reviewed 
by (Vaish, Kore et al. 1998)). The mechanisms and detailed cleavage sites have been determined 
for several of these enzymatic oligonucleotides as shown in Figure 1.4 (reviewed by (Schubert 
and Kurreck 2004)).  Ribozymes have been proposed for several therapeutic applications, 
including targeting cancer(Warashina, Kuwabara et al. 1999), viral(Michienzi, Castanotto et al. 
2003), rheumatoid arthritis(Rutkauskaite, Zacharias et al. 2004), and cardiovascular diseases 
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(Yamamoto, Morishita et al. 2000). Since ribozymes and deoxyribozymes are nucleic acids, they 
are easily degraded in the cells.  Therefore, modifications to the backbone and sugars are made to 
facilitate their survival so that they may carry out their intended purpose.  However, 
modifications can cause conformational changes that possibly stop catalytic activity of the 
ribozymes, thus the modifications must be chosen wisely (reviewed by (Schubert and Kurreck 
2004)).  
 
Figure 1.4. Structures for Ribozymes and DNAzymes(Schubert and Kurreck 2004).  
 
1.3.1 Classes of Ribozymes/Deoxyribozyme and Production of Cleavage 
 The size of the ribozyme and the products made during cleavage determine the class of 
the ribozyme.  Large ribozymes are comprised of hundreds of nucleotides with the largest being 
3000 nucleotides (reviewed by (Schubert and Kurreck 2004)).  The hydrolyzed products contain 
a hydroxyl group on the 3’ end and a phosphate group on the 5’ end.  The large ribozymes 
include self-splicing group I and group II introns and the RNA component of RNase P (reviewed 
7 
 
by (Tanner 1999)).  Self splicing group I introns perform splicing in two steps using a 
transesterification reaction.  Although the exact mechanism for group II introns is not known, the 
intron uses a nucleophilic attack on the splice site ultimately forming a lariat-type structure.  
RNase P cleaves a strand after an external guide sequence binds to the sequence of choice 
(reviewed by (Schubert and Kurreck 2004)).  Small ribozymes are comprised of 30 to 150 
nucleotides.  The small ribozymes have distinct structures, but they all contain specific cleavage 
sites shown in Figure 1.4 (reviewed by (Schubert and Kurreck 2004)). These molecules produce 
products that contain 2’-3’-cyclic phosphate and a 5’ hydroxyl group.  The small ribozymes 
include hammerhead ribozymes(Haseloff and Gerlach 1988), hairpin ribozymes(Hegg and Fedor 
1995), hepatitis delta virus ribozymes(Wadkins and Been 2002), and varkud satellite 
ribozymes(Saville and Collins 1990).  
 Santoro et al. found the most robust deoxyribozyme known to date, named 10-23 
DNAzyme.  As shown in Figure 1.4, it has 15 nucleotides making up the loop and catalytic core 
flanked by two extended substrate recognition arms with 6-12 nucleotides on either side of the 
core to ensure complementary pairing to its intended target (reviewed by (Kurreck 2003)).  
Specifically, the 10-23 DNAzyme cuts between a pyrimidine and a purine (Joyce 2001).  An 
unmodified DNAzyme lasted 2 hours in serum while an added inverted nucleotide at the 3’ end 
increased the lifespan to 20 hours(Sun, Cairns et al. 1999).  The biggest advantage of using 
deoxyribozymes is the ease of synthesis and handling over ribozymes (reviewed by (Schubert 
and Kurreck 2004)).  The 10-23 DNAzyme specifically cuts single-stranded RNA that is 
complementary to its two extended substrate recognition arms. In this project, the 10-23 
DNAzyme’s complementary target is a KRAS mutant mRNA product.  
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1.4 SNP-CONJUGATE TARGET  
This project is focused on designing a nanoparticle drug delivery system based on the 
gene silencing effects of a 10-23 deoxyribozyme(Santoro and Joyce 1998).  The drug delivery 
vehicle, SNP, is functionalized with a thiol-modified deoxyribozyme with internal 
photocleavable linkers(Brown, Qureshi et al. 2013).  The internal photocleavable linkers are 
essential to the spatiotemporal control of the release of the gene silencing 
deoxyribozymes(reviewed by(Pelliccioli and Wirz 2002)).   
The original proposed plan shown in Figure 1.5 targeted miRNA 125b(Zhou, Liu et al. 2010).  It 
was hypothesized that the blockage of  miRNA 125b via DNAzyme cleavage and the addition of 
naturally-formulated rubusoside-Paclitaxel would offer a means to sensitize targeted cancer cells.  
Thus, new chemotherapeutic treatments could be explored.  miRNA 125b is an important 
component in breast cancer cell lines that cleaves the Bak1 mRNA, responsible for 
apoptosis(Zhou, Liu et al. 2010).  Three DNAzymes were synthesized to cut miRNA 125b:1) 
same core as the 10-23 DNAzyme and the recognition arms with complimentary bases, 2) 
modified core to the DNAzyme with wobble base pairs and shorter complementary recognition 
arms, 3) modified core to the DNAzyme with wobble base pairs and longer complementary 
recognition arms.  None of the DNAzymes were successful in cutting the mRNA even though 
buffer conditions, time conditions, and concentration conditions were varied.  Breast cancer cell 
lines, MDA-MB-231 and MDA-MB-435, were proposed to be treated with increasing doses of 
naturally-formulated rubusoside-Paclitaxel to form sensitive and resistant cell lines.  The cell 
lines used started at high passage numbers and did not survive after two weeks of splitting. 
The alternate approach is targeting the mutant K-Ras gene as shown in Figure 1.3, a 
critical component that encodes signal transduction pathway proteins causing pancreatic, 
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Figure 1.5. Aims of original project included gene regulated chemotherapy using nanoscale DNA 
conjugates focused on SNP-Conjugate target miRNA125b. 
colorectal, endometrial, biliary tract, lung, and cervical cancers(Yu, Wang et al. 2009).  This 
project is hypothesized to work since the pyrimidine-purine pair to be cut by the K-Ras 10-23 
DNAzyme is a ‘G-U’ pair, unlike the ‘A-C’ pair to be cut by the miRNA 125b DNAzyme (Yu, 
Wang et al. 2009, Zhou, Liu et al. 2010). In comparison to the original Ras gene, the mutant K-
Ras gene has a point mutation with a uracil nucleotide substituted for a guanine nucleotide.  Due 
to that specific change, a 10-23 deoxyribozyme can hybridize to the pyrimidine-purine site and 
cleave the mutant K-Ras mRNA (Yu, Wang et al. 2009).   “AU = GU > GC >> AC” is the pairs 
decreasing the effectiveness of a deoxyribozyme cutting suggested by Cairns et al(Cairns, King 
et al. 2003).  The K-Ras 10-23 DNAzyme will be used to prime mutant K-RAS colon and breast 
cancer cells to be more impacted by the addition of doxorubicin.   
The addition of UV light will increase uncaging the DNAzyme from silver nanoparticles, 
thus allowing for an effective therapy treatment.  The addition of 11-Mercaptoundecanoic acid 
backfilling will decrease aggregation of particles and increase DNAzyme packing.  Johnson et 
Drug Delivery 
+
 
Paclitaxe
l 
northgatemedicalpc.com 
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al. used 11-mercaptoundecanoic acid to increase homogeneous dispersion of silver nanoparticles 
in their study(Johnson Jr, Kang et al. 2008).   Paclitaxel will not be an appropriate option for 
treatment since taxol works through the microtubule network and so does the expression of the 
K-Ras proteins(Thissen, Gross et al. 1997, Chen, Otto et al. 2000).  The colon cancer cell lines 
system include control lines, HT29 and HEK293, and treated lines, SW480 and SW620.  HT29 
and HEK293 do not have positive expression of the K-Ras mutant gene.  SW620 and SW480 
cell lines express the KRAS mutant ras protein in codon 12. The breast cancer cell lines system 
includes a control line, MCF-7, and treated line, MDA-MB-231.  MCF-7 does not have positive 
expression of the K-Ras mutant gene.  MDA-MB-231 cell line express the KRAS mutant ras 
protein in codon 13.  
1.4.1 miRNA 
miRNA containing a sequence on average of 22 nucleotides long has been found to use 
the RNAi pathway in mammalian systems(Elbashir, Harborth et al. 2001).   miRNAs are 
endogenous regulators of gene expression.  miRNA molecules are derived from primary miRNA 
and cleaved by Drosha, an RNase III enzyme, into precursor miRNA in the nucleus(Lee, Ahn et 
al. 2003).  The structure forms into a hairpin, which is then exported into the cytoplasm.  Dicer 
cleaves the precursor miRNA into the double stranded miRNA that takes part in the RNAi 
pathway (reviewed by (Lingel and Sattler 2005)).  It includes in its structure overhanging parts at 
the ends of the sequences.  The 3’ ends have hydroxyl groups and the 5’ ends have phosphate 
groups. miRNAs act in two different ways (reviewed by (He and Hannon 2004)).  If their 
sequences are not perfectly complementary to their intended target, they stop translation of a 
protein by blocking the ribosome.  However, if their sequence is completely complementary to 
the target, the miRNA can induce mRNA degradation using the RNA-inducing silencing 
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complex(Hammond 2005, Lingel and Sattler 2005).  The RISC complex is comprised of several 
proteins including Argonaute 2, which aids in the cleavage of mRNA (Hammond 2005).  
Classically, it was thought that mRNA was broken down in the cytoplasm following translation; 
however recent studies demonstrate that mRNA degradation occurs in processing bodies (Marx 
2005). 
RNAi Pathway  
 
 RNA interference (RNAi) performs its regulation post-transcriptionally (Hammond 
2005). In 1991, Fire et al. first demonstrated the RNAi phenomenon by blocking the expression 
of two genes for myofilament proteins present in C. elegans body wall muscles (Fire, Albertson 
et al. 1991).  Two key disadvantages to the RNAi pathway are more commonly proper delivery 
but also evading off-target effects (reviewed by (Hannon and Rossi 2004)). The myriad targets 
currently explored using gene silencing by the RNAi pathway include HIV(Jacque, Triques et al. 
2002), viral hepatitis(McCaffrey, Nakai et al. 2003), cancer(Ngo, Davis et al. 2006), and genetic 
diseases(Miller, Gouvion et al. 2004).   
1.4.2 KRAS mRNA 
K-RAS gene encodes the eventual translation of the KRAS protein, an oncogene 
important for regulating cell division (Reviewed by(Dahabreh, Terasawa et al. 2011)).  
Oncologists report most KRAS mutations on codons 12 and 13, and more rare KRAS mutations 
on codons 61 and 146 (Reviewed by (Allegra, Jessup et al. 2009)).  The KRAS protein is a part 
of the RAS/MAPK pathway.  Through this pathway, signals are sent causing growth or division 
and eventually differentiation.  Specifically, KRAS protein is a GTPase that acts as a switch 
when combined to either GTP or GDP.  Wild type cell lines have normal conversions on and off 
in normal KRAS genes.  On the other hand, mutant cell lines are continuously dividing due to 
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the inactivation of this essential cellular division toggle switch.  These mutant signal transduction 
pathway proteins are major causes for pancreatic, colorectal, endometrial, biliary tract, lung, and 
cervical cancers (Reviewed by (Yu, Wang et al. 2009)).  Certain therapies are not recommended 
due to the KRAS mutation, thus other therapies are required.  Specifically, Allegra et al. did not 
recommend the use of anti-EGFR monoclonal antibody therapy (Reviewed by (Allegra, Jessup et 
al. 2009, Dahabreh, Terasawa et al. 2011)). Yu et al. suggest a treatment of DNAzyme and 
doxorubicin as alternative method of treatment(Yu, Wang et al. 2009).  Our project suggests a 
step further with the addition of a silver nanoparticle carrier for ease of entrance into cancerous 
cells and spatial and temporal control. 
1.5 DRUG FOR STAGGERED GENE-MEDIATED CHEMOTHERAPY  
1.5.1 Paclitaxel 
Paclitaxel is a chemotherapeutic agent currently used for breast cancer therapy whose 
action is an inhibition of microtubule formation and disassembly thus inducing 
apoptosis(Rowinsky, Cazenave et al. 1990, Perez 1998).  Paclitaxel is isolated from the bark of 
the yew, Taxus brevifolia (Wani, Taylor et al. 1971). The scarce amount of Paclitaxel available 
to early studies led to restricted clinical trials.  However, the drug is now semi-synthesized from 
baccatin III, a precursor to Paclitaxel(Holton, Biediger et al. 1995).  Paclitaxel is used in the 
treatment of a variety of cancers, including carcinomas of the ovary, breast, lung, head and neck, 
bladder and cervix, melanomas, and AIDS-related Karposi’s sarcoma (reviewed by (Jennewein 
and Croteau 2001)).  Liu et al. have had success with Paclitaxel by formulating it with a 
naturally-derived solubilizing agent, rubusoside, to facilitate intracellular delivery (LIU 2009).  
Rubusoside is a sweetener extracted from the leaves of the Rubus Suavissimus S. Lee 
plant(Sugimoto, Sato et al. 2002).  Rubusoside has shown promise for being less toxic than 
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existing solubulizers such as ethanol (reviewed by (Singla, Garg et al. 2002)).  In our originally 
proposed study, SNP-DNAzyme and rubusoside-Paclitaxel will be delivered in staggered mode, 
allowing the DNAZyme to degrade miRNA 125b and sensitizing the cell to Paclitaxel before the 
drug’s application. SNP-DNAzyme will be delivered and photoactivated in the breast cancer cell 
cultures 24 to 48 hours before the dose of rubusoside-Paclitaxel is applied.  The effectiveness of 
photoreleasing the DNAzyme from the SNP and initiating gene-regulation of miRNA 125b will 
enhance the sensitivity of breast cancer cells to Paclitaxel, and demonstrate potential for 
targeting this therapy. 
miRNA125b 
The mechanism underlying cancer cells resistance to Taxol is not fully understood. Zhou 
et al. demonstrated that miRNAs have an effect on the role of breast cancer resistance(Zhou, Liu 
et al. 2010). miRNA 125b is upregulated in Taxol-resistant cancer cells, leading to paclitaxel 
drug resistance.  miRNA 125b inhibits Taxol-induced cytotoxicity and apoptosis.  Specifically, it 
targets pro-apoptotic Bcl-2 antagonist killer 1 (Bak1).  Downregulation of Bak1 suppresses 
taxol-induced apoptosis and increases resistance to taxol.  By cleaving miRNA125b, Bak1 is 
restored; thereby, paclitaxel sensitivity increases and the apoptosis of breast cancer cells 
increases . 
1.5.2 Doxorubicin 
Paclitaxel will not be an appropriate option for treatment since taxol works through the 
microtubule network and so does the expression of the K-Ras proteins(Thissen, Gross et al. 
1997, Chen, Otto et al. 2000). Doxorubicin is an excellent alternative chemotherapeutic agent 
since it functions by intercalating DNA.  Doxorubicin is an anthracycline antibiotic, administered 
intravenously (Reviewed by (Aubel-Sadron and Londos-Gagliardi 1984)).  Doxorubicin can be 
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delivered liposome-encapsulated or as a hydrochloride salt (Reviewed by(Gabizon, Shmeeda et 
al. 2003)).   Doxorubicin is derived from a bacterial species Streptomyces using a chemical 
semisynthesis(Guilfoile and Hutchinson 1991).  The drug is used in the treatment of several 
cancers including breast and colon cancer (Reviewed by (Travis, Curtis et al. 1991, Khasraw, 
Bell et al. 2012)). In the final study, SNP-DNAzyme and Doxorubicin-HCl were delivered in 
staggered mode, allowing the DNAzyme to degrade KRAS mRNA and sensitizing the cell to 
doxorubicin before the drug’s application. SNP-DNAzyme will be delivered and photoactivated 
in the corresponding colon and breast cancer cell lines 24 hours before the dose of doxorubicin is 
applied.  The effectiveness of photoreleasing the DNAzyme from the SNP and initiating gene-
regulation of KRAS mRNA will enhance the sensitivity of the colon and breast cancer cells to 
doxorubicin, and demonstrate potential for targeting this therapy. 
1.6 SNP ASSISTED TRANSPORT BACKGROUND  
In this application, silver nanoparticles(SNPs) serve as carriers for the oligonucleotides to 
facilitate their cellular delivery.  If the SNPs are formed within the range of 1-100 nm in 
diameter, they have excellent cellular delivery capabilities because particles of that size are not 
generally removed by the reticuloendothelial system (reviewed by (Bawarski, Chidlowsky et al. 
2008)).  In general, the number of applications utilizing nanoparticles has increased greatly due 
to improvements in ease of their synthesis and bioconjugation (reviewed by (Biju, Itoh et al. 
2008)).  A noble metal nanoparticle has distinctive electronic and photonic properties (reviewed 
by (Hutter and Fendler 2004)).  Assays can be made using these distinctive properties of SNPs in 
order to evaluate the DNA-functionalized SNPs.  
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1.6.1 Properties of Silver Nanoparticles 
 The advantageous photoelectric properties of a SNP include high scattering efficiency, 
large extinction coefficients and localized surface plasmon resonance (LSPR) by (Yguerabide 
and Yguerabide 1998, Hutter and Fendler 2004).  When these properties are present, as in the 
case of using colloidal silver nanoparticles, there is an additive effect causing surface enhanced 
spectroscopy, which enables qualitative or possibly quantitative analysis of low levels of target 
analytes (Munro, Smith et al. 1995, Munro, Smith et al. 1995) .  These properties ultimately 
assist in driving the reactions for drug delivery since the electric field will cause strain to the 
bonds of the nanoparticle, allowing for easier release of functionalized oligonucleotides(Chen 
and Goodman 2004, Eustis and El-Sayed 2006). 
High Scattering Efficiency and Large Extinction Coefficient 
 Gold and silver particles are extremely advantageous to use as tracers because they are 
light-scattering particles; they act similarly to fluorescent molecules with the addition of being 
sensitive to concentrations as low as 10
-16
 M (Yguerabide and Yguerabide 1998).   Yguerabide et 
al. showed that silver has larger extinction coefficients than gold for particles of similar size as 
shown in Table 1.1. Yguerabide et al. also reported that silver scatters light 10 times stronger 
than gold. Yguerabide et al. reported in Table 1.2 the molar extinction coefficients of the SNPs 
enlarged with increasing diameter.  The surface plasmon resonance of 60 nm SNPs displays a 
strong absorbance peak at 420 nm wavelength allowing for the use of UV-vis spectroscopy for 
characterization of the nanoparticles for this study.  The strong scattering capability and large 
extinction coefficient allows for quantitation of silver concentration using the Beer-Lambert law 
(A= εcl).  Where A is absorbance, ε is the extinction coefficient, c is the concentration of the 
absorbing molecule, and l is the optical pathlength. 
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Table 1.1. Differences in Rel Csca (Yguerabide and Yguerabide 1998). 
 
 
Table 1.2. Differences in Csca for increasing sizes of SNPs (Yguerabide and Yguerabide 1998). 
 
Localized Surface Plasmon Resonance 
            Localized surface plasmons are charge density oscillations present only on metallic 
nanoparticles and metallic nanostructures (reviewed by (Hutter and Fendler 2004)).  As shown in 
Figure 1.6, a colloidal silver nanoparticle is excited by an electric field at a particular wavelength 
causing an oscillation of the outermost electrons of the metal (Kelly, Coronado et al. 2003).  
Strong light scattering occurs due to resonance causing intense surface absorption bands to 
appear; the overall effect is surface enhanced spectroscopy (reviewed by (Willets and Van 
Duyne 2007)).  In general, the material, size, and shape of the nanoparticle are distinctly 
characterized by certain absorption maxima and color due to these surface plasmon absorption 
bands (reviewed by (Hutter and Fendler 2004)).   
 
[Type a quote from the document or the summary of an interesting point. You can position the 
text box anywhere in the document. Use the Text Box Tools tab to change the formatting of the 
pull quote text box.] 
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Figure 1.6. Surface plasmon oscillation of metal sphere (Kelly, Coronado et al. 2003). 
 
1.7 THIOL LINKAGE BACKGROUND  
Functionalization of nanoparticles with specific biomolecules can be accomplished through 
various methods employing varying strengths of bonds in an aqueous environment (Goldys 
2009).  Electrostatic attraction and adsorption methods are the simplest, but the most stable 
method is a covalent linkage between the intended biomolecule and its compatible nanoparticle 
surface groups (reviewed by (Bawarski, Chidlowsky et al. 2008). Brown et al. use the binding of 
thiols to the metal nanoparticle surface through a covalent bond as their method used to connect 
the oligonucleotide to the silver nanoparticle(Herne and Tarlov 1997). The covalent bond 
between the thiol and SNP can be detected by the changes induced in the electron density on the 
SNP surface, resulting in a shift in the surface plasmon absorption maximum (reviewed by 
(Eustis and El-Sayed 2006)). 
1.8 PHOTOACTIVATED CONTROL LINKERS BACKGROUND  
      Many biomolecules and second messengers can be chemically modified in order to block 
their activity.  This can be performed by adding blocking groups or photocleavable groups to the 
compound which alter its structure and thus biochemical activity.  Photocleavable groups have 
advantages over the blocking groups since they can work on highly sensitive molecules that are 
normally incompatible with acids or bases (Dmochowski and Tang 2007).  Caged compounds 
are molecules with inactive function rendered by attachment of photocleavable groups (reviewed 
by (Ellis-Davies 2007)).  Ghosn et al. used 1-(4,5-dimethoxy-2-nitrophenyl) ethyl ester 
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(DMNPE) to block transcription of DNA plasmids; DMNPE was released using light. A 
fluorescence based assay was used to detect hybridization of the unblocked oligonucleotide. 
Activity of ribozymes have been modulated with a caged adenosine that blocked enzymatic 
activity until photoactivation (Chaulk and MacMillan 1998).  Dmochowski and coworkers have 
worked on photoactivating caged fluorescent oligodeoxynucleotides, caged peptide nucleic acid 
oligonucleotides, and more currently caged 10-23 DNAzymes (Tang and Dmochowski 2005, 
Tang and Dmochowski 2007, Richards, Seward et al. 2010).  More specifically, the caged 10-23 
DNAzyme has a light-induced strand break that causes activation of the DNAzyme when it is 
photocleaved(Richards, Seward et al. 2010). 
Caged compounds can also act as linkers and be termed tethered blockage.  When 
Pelliccioli and Wirz reviewed photoremovable protecting groups, they suggested good 
photoactivating groups needed several factors. The photoactivation should occur with high 
quantum yield, the chromophore’s absorption coefficients should be appropriate to the depth of 
penetration needed for the sample, photoactivated byproducts should be biocompatible and 
biologically inert, the release rate for the active compound must be within the timeframe being 
evaluated, and caged compounds should be soluble in water and pass through appropriate cell 
membranes (reviewed by (Pelliccioli and Wirz 2002)).    In this project, the photocleavable 
linkers are between the nanoparticle and DNAzyme oligonucleotides.  Once the constructed 
compound is photoactivated with UV light, the 1-(2-nitrophenyl)ethyl (NPE)-based 
photocleavable linker undergoes photolysis as shown in Figure 1.7 (reviewed by (Pelliccioli and 
Wirz 2002)); thereby, the DNAzyme oligonucleotide is released from the nanoparticle.  
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Figure 1.7. Mechanism of 1-(2-nitrophenyl)ethyl (NPE)-based photocleavable linker (Berry & 
Associates Manual, 2008) . 
  
1.9 GENE-SILENCING OLIGONUCLEOTIDE  
In this project, characterization of the stability and activity of citrate and HPC silver 
nanoparticle drug delivery systems constructed for the release of a photolabile DNA 
oligonucleotide were tested to show the improvement of temporal and spatial control efficiency 
of the designed construct.  The drug delivery vehicle, silver nanoparticle, is functionalized with a 
thiol-modified 10-23 DNAzyme oligonucleotide with internal photocleavable linkers.  The 
intended target for hybridization and gene silencing control is K-RAS mRNA.  The internal 
photocleavable linkers permit spatiotemporal control release of the gene silencing K-RAS 10-23 
DNAzyme oligonucleotides.  HPC SNPs are more reliable as an oligonucleotide carrier than the 
citrate SNPs. To increase more protection to the DNAzyme, the SNPs were backfilled with 11-
mercaptoundecanoic acid.  Our results suggest the photoactivatable HPC SNP-10-23 DNAzyme 
oligonucleotide may enable a light-targeted gene silencing therapy if a robust cell line system 
can be identified for its validation. 
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CHAPTER 2. SYNTHESIS AND CHARACTERIZATION OF 
PHOTOACTIVATABLE SNP-DNAZYME 
 
2.1 INTRODUCTION 
Therapeutic approaches which utilize the internal machinery inherently present in cells 
are being increasingly explored as an alternative to the use of more standard pharmacological 
agents. Currently, several methods focus comprehensively on the mRNA level by preventing 
their translation into proteins. These methods are often implemented for the most critical aspects 
of gene silencing: halting or preventing production of proteins mediating disease(reviewed by 
(Bianco and Robey 2001)).  The molecular species are most often in nucleic acid form, including 
antisense oligonucleotides, ribozymes, DNAzymes, and several small RNA species that target 
the RNA interference pathway (reviewed by (Kurreck 2003)). While many of these approaches 
are still only being evaluated in the laboratory, several have developed to the clinical stages 
(reviewed by (Akkina, Banerjea et al.)).  
        Each class of gene silencing candidates is distinct in the cellular machinery it uses 
and its specific mechanism of mRNA disruption. However, challenges exist for each class such 
as finding accessible sites on the target RNA for therapeutic oligonucleotide hybridization,  
protecting oligonucleotides from degradation by enzymes, and achieving cellular uptake and 
accurate intracellular localization (reviewed by (Kurreck 2003)).  
        The original proposed plan in this project targeted the disruption of miRNA 
125b(Zhou, Liu et al. 2010) as strategy for treatment of cancer. It was hypothesized that the 
cleavage of miRNA 125b via DNAzyme action, followed by the administration of naturally-
formulated rubusoside-Paclitaxel, would offer a means to sensitize targeted cancer cells. miRNA 
125b is an important signal pathway regulator, which in breast cancer cells, cleaves Bak1 
27 
 
mRNA, which is responsible for apoptosis(Zhou, Liu et al. 2010).  Three DNAzymes were 
synthesized to cut miRNA 125b:1) one with the same core as the 10-23 DNAzyme and the 
recognition arms with complimentary bases, 2) a modified core to the DNAzyme with wobble 
base pairs and shorter complementary recognition arms, 3) a modified core to the DNAzyme 
with wobble base pairs and longer complementary recognition arms. None of these DNAzymes 
were successful in cleaving the substrate RNA despite evaluation in varying buffer, time, and 
concentration conditions. 
Thus an alternate approach was explored, a DNAzyme known to target the mutant K-Ras 
gene, which is a critical signal transduction pathway that when mutated leads to pancreatic, 
colorectal, endometrial, biliary tract, lung, and cervical cancers(Yu, Wang et al. 2009). The basis 
of this hypothesis is that the pyrimidine-purine pair to be cut by the K-Ras 10-23 DNAzyme is a 
‘G-U’ pair, unlike the ‘A-C’ pair to be cut by the miRNA 125b DNAzyme (Yu, Wang et al. 
2009, Zhou, Liu et al. 2010). In comparison to the original Ras gene, the mutant K-Ras gene has 
a point mutation with a U substituted for a G. This mutation allows a 10-23 deoxyribozyme to 
hybridize to the pyrimidine-purine site and cleave the mutant K-Ras mRNA (Yu, Wang et al. 
2009).   Modification of these nucleotide pairs has been explored by Cairns et al., demosnstrating 
that AU = GU > GC >> AC in the effectiveness of cleavage. (Cairns, King et al. 2003). The K-
Ras 10-23 DNAzyme will be used in this project to sensitize mutant K-RAS colon and breast 
cancer cells to the chemotherapeutic doxorubicin.  
In this application, SNPs serve as oligonucleotides carriers to facilitate their intracellular 
delivery. If the SNPs are formed within the range of 1-100 nm in diameter, they have excellent 
cellular delivery capabilities because particles of that size are not generally removed by the 
reticuloendothelial system (reviewed by (Bawarski, Chidlowsky et al. 2008)). In general, the 
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number of applications utilizing nanoparticles has increased greatly due to improvements in ease 
of their synthesis and bioconjugation (reviewed by (Biju, Itoh et al. 2008)). Noble metal 
nanoparticles have distinctive electronic and photonic properties (reviewed by (Hutter and 
Fendler 2004),) which can be utilized for this application.  These properties include high 
scattering efficiency, large extinction coefficients, and localized surface plasmon resonance 
(LSPR) (Yguerabide and Yguerabide 1998, Hutter and Fendler 2004). Colloidal silver 
nanoparticles possess the additive benefit of surface enhanced spectroscopy, which enables 
qualitative and quantitative analysis of low levels of target analytes (Munro, Smith et al. 1995, 
Munro, Smith et al. 1995) . These properties ultimately assist in driving the reactions for drug 
delivery since the electric field will cause strain to the bonds of the nanoparticle, allowing for 
easier release of functionalized oligonucleotides(Chen and Goodman 2004, Eustis and El-Sayed 
2006).   
DNAzyme oligonucleotides conjugated to the surface of SNP via thiol-metal linkages are 
thought to pack densely(Qureshi, Monroe et al. 2013), thus protecting them from enzymatic 
degradation .  Johnson et al. reported 11-mercaptoundecanoic acid aided the homogeneous 
dispersal of silver nanoparticles (Johnson Jr, Kang et al. 2008) addressing an important need for 
reduced aggregation to aid in a greater packing density.  TEM imaging showed packing density 
was enhanced by “backfilling” the oligonucleotide-functionalized particle via subsequent 
addition of the alkane thiol 11-mercaptoundecanoic acid.  In addition, the DNA construct 
includes a photocleavable nitrobenzyl group to permit oligonucleotide release from the SNP with 
UV light exposure. The SNP-DNAzyme construct was designed to be evaluated in a system 
requiring targeted gene silencing, whereby precise light exposure offers spatiotermporal control. 
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This project has significance because it addresses the need to develop effective means of 
delivering therapeutic oligonucleotides to targeted cells with high efficiency and precision. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
DNAzyme and RNA materials 
Silver nanoparticles were functionalized with thiol-modified miRNA 125b DNAzyme 
ordered from Integrated DNA Technologies (DA: 5'- TCA CAA GTT AGG GGG CTA GCT 
ACA ACG ACT CAG GGA -3' and DC: 5'- A GTT AGG I GG CTA GCT ACA ACG A U T 
CAG GGA -3', IDT, Coralville, IA) or EXIQON (LA: 5'- TCACAAGT+TAG+G/ideoxyI/ 
GGCTAGCTACAA CGA/ideoxyU/T+CA+GGGA-3', Bold letters have modification locked 
nucleic acid, Woburn, MA) based on miRNA125b reported by Zhou et al.(Zhou, Liu et al. 
2010). Silver nanoparticles were functionalized with thiol-modified KRAS DNAzymes ordered 
from Integrated DNA Technologies (5'- CTA CGC CAA GGC TAG CTA CAA CGA AGC 
TCC AAC T /3ThioMC3-D/ -3', IDT, Coralville, IA) or Trilink Biotechnologies (5' (TAMRA) 
(C6-NH) CTA CGC CAA GGC TAG CTA CAA CGA AGC TCC AAC T (PC Spacer) T (C3-S-
S-C3) 3', San Diego, CA) based on DNAzyme reported by Yu et al.(Yu, Wang et al. 2009). 
miRNA 125 mRNA were ordered from Integrated DNA Technologies (5'- rUrCrC rCrUrG 
rArGrA rCrCrC rUrArA rCrUrU rGrUrG rA/36-FAM/ -3' or 5'- /TYE665/-TTTTTTTTTT- 
rUrCrC rCrUrG rArGrA rCrCrC rUrArA rCrUrU rGrUrG rA-3', IDT, Coralville, IA) based on 
 complementary sequence to DNAzyme. KRAS mRNA were ordered from Integrated DNA 
Technologies (5'- rArGrU rUrGrG rArGrC rUrGrU rUrGrG rCrGrU rArG -3' or 5'-
/5TYE665/rArGrU rUrGrG rArGrC rUrGrU rUrGrG rCrGrU rArG -3', IDT, Coralville, IA)) 
based on complementary sequence to DNAzyme. 
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Gel Electrophoresis Materials 
Mini-PROTEAN® Tetra cell, Mini-PROTEAN® TBE precast gels (15% 
polyacrylamide, 12-well comb, 20µl/well),  Mini-PROTEAN TBE-Urea precast gels (15% 
precast polyacrylamide gel, 12-well comb, 20µl/well), 10X TBE buffer, and PowerPac™ Basic 
Power Supply were purchased from Bio-Rad (Hercules, CA). Low Molecular Weight Marker 10-
100 nt was purchased from Affymetrix (Santa Clara, CA). Fragment Sizes: 10 nt; 15 nt; 20 nt; 25 
nt; 30 nt; 35 nt; 40 nt; 45 nt; 50 nt; 60 nt; 70 nt;80 nt; 90 nt; 100 nt. 2X Formamide Loading 
Buffer was supplied with the marker. Syber Gold™ stain 10,000X was purchased from 
Molecular Probes via Thermo Fisher Scientific (Rochester, NY). 
Reaction and Stopping Buffer Materials 
Magnesium chloride, Trizma® hydrochloride, and sodium chloride were purchased from 
Sigma Aldrich (St. Louis, MO). Potassium chloride was purchased from Fischer Scientific 
(Pittsburgh, PA). EDTA was purchased from Amresco (Solon, OH).  All solvents purchased 
were for molecular biology. 
Citrate and HPC Silver Nanoparticle Oligonucleotide Materials 
Silver nitrate (Sigma Ultra >99%) and sodium citrate were purchased from Sigma 
Aldrich (St. Louis, MO). PTFE resin-coated magnetic stirring bars were purchased from VWR 
(West Chester, PA). 100 mL Glass syringes used to dispense sodium citrate dropwise to reduce 
silver nitrate in solution were purchased from KD scientific (Holliston, MA). All other glassware 
was purchased through Fisher Scientific (Pittsburgh, PA). Hydroxypropyl cellulose SNPs, 
SmartSilver
TM
AS, was purchased from NanoHorizons Inc (Bellefonte, PA). Silver nanoparticles 
were functionalized with thiol-modified miRNA 125b or KRAS DNAzymes ordered from 
Integrated DNA Technologies (IDT, Coralville, IA) or Trilink Biotechnologies (San Diego, CA). 
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2M Tris-NaCl buffer (pH 8.0) was made up from Biotechnology grade Tris (Amresco Inc, Solon, 
OH) and sodium chloride (Fischer Scientific, Pittsburgh, PA). 11-Mercaptoundecanoic acid was 
ordered from Sigma Aldrich (St. Louis, MO).   
SNP Characterization Materials 
             Transmission Electron Microscopy (TEM) grids were obtained from Electron 
Microscopy Sciences (Hatfield, PA).  Malvern ZEN0040 disposable cuvettes were purchased 
from Malvern (Worcestershire, United Kingdom).  DL-Dithiothreitol, 1M aqueous solution was 
purchased from Sigma Aldrich (St. Louis, MO) 
2.2.2 Methods 
In vitro Photocleavage of DNAzyme Oligonucleotide or SNP-DNAzyme 
miRNA125b DNAzyme and miRNA125b RNA were pooled together (1:1) for 0, 30, and 
60 minutes. KRAS DNAzyme and KRAS RNA were pooled together 0, 30, and 60 minutes.  
KRAS SNP-DNAzyme and KRAS RNA were pooled together 0, 30, and 60 minutes.  50mM 
EDTA pH 7.5 stopping buffer was applied to stop the reactions. Samples were hit with 
ultraviolet light using the High Performance Ultraviolet Transilluminator (UVP, Upland, CA) 
purchased via Fisher Scientific (Pittsburgh, PA). 10µl of sample, Loading Buffer, and DEPC 
water were run in individual wells in the Mini-PROTEAN® TBE precast gels (15% 
polyacrylamide, 12-well comb, 20µl/well) or Mini-PROTEAN TBE-Urea precast gels (15% 
precast polyacrylamide gel, 12-well comb, 20µl/well), in the Mini-PROTEAN® Tetra cell (100V 
native/180V denaturing) with 1X TBE buffer. Low Molecular Weight Marker 10-100 nt was 
loaded in individual wells. Gels were stained in 1X SYBR Gold (30 µl 1XSYBR Gold in 300mL 
1X TBE buffer) for 30 minutes. Samples were visualized on a Typhoon 9410 Variable Mode 
Imager (normal sensitivity, 400 PMT Volts, prescan at 1000 microns pixel size, imaging at 100 
32 
 
microns pixel size) (GE Healthcare, Piscataway, NJ). 488nm laser line was used to image gels 
stained with SYBR Gold (540bp30 filter). 633 nm laser line was used to image gels with RNA 
containing TYE665 (648/666) present (670bp30 filter).   
WCIF Image J Image Processing  
Images were processed and analyzed using WCIF Image J. The mean pixel intensity of one 
line was taken on the left, middle, and right side of each sample. The mean pixel intensities of 
the samples hit with UV divided by the mean pixel intensities of the samples not hit with UV is 
plotted on a bar graph.  
SNP Synthesis 
Citrate-reduced silver nanoparticles were prepared according to the method written by 
Brown et al.(Brown, Qureshi et al. 2013) Hydroxypropyl cellulose SNPs, SmartSilver
TM
AS, was 
purchased from NanoHorizons Inc (Bellefonte, PA). 
SNP Functionalization 
Silver nanoparticles were functionalized by a revised ‘salt-aging’ technique. Thiol-
modified TAMRA(NHSester)-labeled oligonucleotides (543/571, Trilink Biotechnologies) were 
mixed with silver nanoparticles (128ppm) at an oligo-to-particle stoichiometry of 700:1. The 
mixtures incubate at 37°C under rocking conditions for 24 hours to support the beginning of 
oligonucleotide adsorption to the silver nanoparticle by their end thiol bond. Following the 24hr 
incubation period, the SNP-DNAzyme oligonucleotide conjugate solution was first adjusted to 
1% SDS and 25mM phosphate buffer.  Then the SNP-DNAzyme oligonucleotide conjugate 
solution went through a 48hr Tris-buffer based salt-aging process ending in a 80mM NaCl and 
80mM Tris buffer (10ul aliquot additions 7X of a 2M Tris-NaCl buffer pH 8.0 per 48hrs, 10µl 
addition every 3-4 hours) concentration. Functionalized nanoparticles were purified by 
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centrifugation (3 20 minute spins at 7000 RPM) and pellets were resuspended in a modified 
buffer (1% SDS, 50mM Tris-NaCl) prior to experimental analysis.  Purified particles were 
backfilled with 0.169 µM 11-Mercaptoundecanoic acid (1/10 DNAzyme concentration).   
SNP Characterization and Oligonucleotide Surface coverage Methods 
Ultraviolet-Visible Spectroscopy was performed using a Genesys6 UV–Visible 
Spectrophotometer (Thermo Scientific, Madison, WI). 100 µl of various SNP samples were 
pipetted into disposable cuvettes, and the absorbance spectrum of 200-700 nm wavelengths was 
collected.  The peak absorbance of the SNP, at approximately 420 nm(Yguerabide and 
Yguerabide 1998), undergoes a red-shift when functionalized with DNAzyme oligonucleotides.   
Transmission Electron Microscopy (TEM) images were imaged on a JOEL 2011 TM 
(Tokyo, Japan). 5 µL of diluted sample was added to a carbon film 400 square mesh copper grid 
(Electron Microscopy Sciences), and was air dried for 10 minutes. Images were taken at various 
magnifications. TEM images were analyzed using ImageJ. The diameters of nanoparticles of 
each type were measured using digital calipers. 
Dynamic Light Scattering (DLS) was performed using a Malvern Zetasizer nano series 
(Worcestershire, UK).  Hydrodynamic diameters of samples were measured in Malvern 
ZEN0040 disposable cuvettes at 25˚ C. SNP samples were measured in 1% SDS, 50mM Tris-
NaCl. 
Zeta potential was performed using a Malvern Zetasizer nano series (Worcestershire, 
UK). Charges of samples were measured in Zetasizer nano series folded capillary cells at 25˚ C. 
SNP samples were measured in deionized water.   
Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) was performed 
using a Varian Vista MPX (Palo Alto, CA). The masses of a 10mL glass test tube, 100µL of 
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treated SNP samples, 1mL nitric acid, and 10mL of DI water were recorded in an Excel file after 
each additional item was pipetted in. The silver concentrations of triplicate treated samples were 
measured by the Vista MPX. The component densities and the collected silver data were used to 
calculate the concentrations of the treated samples. 
 Oligonucleotide surface coverage was quantified using fluorescence calibrations of 
known concentrations of TAMRA DNAzyme (546/576) in 100 µl volumes. The fluorescence 
was recorded using a Wallac 1420 VICTOR2™ plate reader (Perkin Elmer, Shelton, CT). A 
standard curve was established with results. The concentration of oligonucleotide in the 
experimental samples that were photocleaved or DL-Dithiothreitol (DTT)-treated could then be 
determined. Surface coverage was determined based on a method using ICP-OES results and 
oligonucleotide concentration reported by Qureshi et al.(Qureshi, Monroe et al. 2013).  
Statistical analysis 
All results were expressed as mean ± % standard error.  
2.3 RESULTS AND DISCUSSION 
This project is focused on designing a nanoparticle drug delivery system based on the 
gene silencing effects of a 10-23 deoxyribozyme(Santoro and Joyce 1998).  The drug delivery 
vehicle, silver nanoparticle(SNP), is functionalized with a thiol-modified deoxyribozyme with 
internal photocleavable linkers(Brown, Qureshi et al. 2013).  The internal photocleavable linkers 
are essential to the spatiotemporal control of the release of the gene silencing 
deoxyribozymes(reviewed by(Pelliccioli and Wirz 2002)).   
The original proposed plan in this project targeted the disruption of miRNA 125b (Zhou, 
Liu et al. 2010) as strategy of treatment for cancer.  It was hypothesized that the cleavage of 
miRNA 125b via DNAzyme action, followed by the administration of naturally-formulated 
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rubusoside-Paclitaxel, would offer a means to sensitize targeted cancer cells. miRNA 125b is an 
important signal pathway regulator, which in breast cancer cells, cleaves Bak1 mRNA, which is 
responsible for apoptosis(Zhou, Liu et al. 2010).  As shown in Figure 2.1, three DNAzymes were 
synthesized to cut miRNA125b:1) same core as the 10-23 DNAzyme and the recognition arms 
with complimentary bases, 2) modified core to the DNAzyme with wobble base pairs and shorter 
complementary recognition arms, 3) modified core to the DNAzyme with wobble base pairs and 
longer complementary recognition arms.  None of these DNAzymes were successful in cleaving 
the substrate RNA despite evaluation in varying buffer, time, and concentration conditions.  
Breast cancer cell lines, MDA-MB-231 and MDA-MB-435, were proposed to be treated with 
increasing doses of naturally-formulated rubusoside-Paclitaxel to form sensitive and resistant cell 
lines. The cell lines used started at high passage numbers and did not survive after two weeks of 
splitting.  
 
Figure 2.1. Hybridization of the mi125b DNAzyme to the miRNA125 mRNA. DNAzymes 
synthesized to cut miRNA 125b mRNA: A) 10-23 DNAzyme core,  B) same core as the 10-23 
DNAzyme and the recognition arms with complimentary bases, C) modified core to the 
DNAzyme with wobble base pairs and longer complementary recognition arms with locked 
nucleic acid modifications, and D) modified core to the DNAzyme with wobble base pairs and 
shorter complementary recognition arms. 
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 Figure 2.2 shows that anti-miRNA125b linked with the fluorescent molecule 6-FAM 
(lane 2) was the same size as DNAzyme A (lane 5) and LNAzyme A (lane 7), thus the RNA 
could not be used for determination of cutting cleavage effectiveness.  Anti-miRNA125b linked 
with TYE665 (lane 3) showed a significant difference in size compared to the other DNAzyme 
controls.   
 
Figure 2.2. Overlay of 2 images (SYBR Gold stained and 6FAM-488nm laser & 520bp40 filter 
and TYE665-633nm laser & 670bp30): miRNA125b RNA and DNAzyme controls.  Lanes 1 and 
4) Low Molecular Weight Ladder 10-100 nt; Lane 2) 6FAM  miRNA125b (520bp40); Lane 3) 
TYE665 miRNA125b (670bp30); Lane 5) DA; Lane 6) DC; and Lane 7)LA.    
 
Figure 2.3 shows the ineffectiveness of LNAzyme A cutting TYE665 anti-miRNA125b. 
LNAzyme A was even concentrated 50:1 compared to the TYE^^% anti-miRNA 125b.  The gel 
also shows the timed reaction of 60 minutes, including the samples placed in several reaction 
buffers. 
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Figure 2.3. Overlay of 2 images (SYBR Gold stained -488nm laser & 520bp40 filter and 
TYE665-633nm laser & 670bp30): 50:1 LA DNAzyme:TYE665 miRNA125b RNA cleavage 
reaction for 60 minutes.  Lanes 1) TYE665 miRNA125b (670bp30); Lane 2) LA DNAzyme; 
Lane 3) Low Molecular Weight Ladder 10-100 nt; Lane 4) 50:1 LA DNAzyme; RNA in B2; 
Lane 5) 50:1 LA DNAzyme; RNA in B3; Lane 6) 50:1 LA DNAzyme; RNA in B4; and Lane 7) 
50:1 LA DNAzyme; RNA in B5.   Buffers: B2-150mM NaCl & 2 mM MgCl2; B3-150mM KCl 
& 2 mM MgCl2; B4-60mM NaCl & 2 mM MgCl2; and B5-60mM KCl & 2 mM MgCl2). 
 
An alternate approach was explored, a DNAzyme known to target the mutant K-Ras gene 
as shown in Figure 2.4, which is a critical signal transduction pathway that when mutated leads 
to pancreatic, colorectal, endometrial, biliary tract, lung, and cervical cancers(Yu, Wang et al. 
2009).  The 10-23 DNAzyme was shown to be effective in the studies conducted by Yu et al.  
The basis of this hypothesis is that the pyrimidine-purine pair to be cut by the K-Ras 10-23 
DNAzyme is a ‘G-U’ pair, unlike the ‘A-C’ pair to be cut by the miRNA 125b DNAzyme shown 
in Figure 2.1 (Yu, Wang et al. 2009, Zhou, Liu et al. 2010). In comparison to the original Ras 
gene, the mutant K-Ras gene has a point mutation with a U substituted for a G. This mutation 
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allows a 10-23 deoxyribozyme to hybridize to the pyrimidine-purine site and cleave the mutant 
K-Ras mRNA(Yu, Wang et al. 2009).   Modification of these nucleotide pairs has been explored 
by Cairns et al., demosnstrating that AU = GU > GC >> AC in the effectiveness of cleavage 
(Cairns, King et al. 2003).  The K-Ras 10-23 DNAzyme will be used in this project to sensitize 
mutant K-RAS colon and breast cancer cells to the chemotherapeutic doxorubicin. The 
additional light will increase uncaging the DNAzyme from silver nanoparticles, thus allowing for 
an effective therapy treatment. Paclitaxel will not be an appropriate option for treatment since 
taxol works through the microtubule network and so does the expression of the K-Ras 
proteins(Thissen, Gross et al. 1997, Chen, Otto et al. 2000).   
Figure 2.4. Hybridization of the K-Ras DNAzyme to the Mutant K-Ras Gene. 
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The design of the KRAS DNAzyme (KRAS DZ) construct evaluated several elements: 
effective cleavage ability, thiol modification (thiolDZ), incorporation of the photocleavable 
linker (PC DZ), and TAMRA fluorophore conjugation (TAMRA DZ), effective removal of the 
thiolDZ from SNP using DTT, optimization of the coverage of DNAzyme oligonucleotide 
surrounding the citrate or HPC SNP surface; photolysis of the nitrophenylethyl internal 
photocleavable linker, and protection of the oligonucleotide from enzymatic degradation.   
Effective cleavage ability of the KRAS DNAzyme is shown in Figure 2.5. Figure 2.5 
displays the electrophoresis gel of the combination of 10-23 DNAzyme and its target K-Ras 
mRNA substrate in 3 different buffers. The first two lanes to the left of the ladder are control 
wells of pure DNAzyme and RNA, respectively. A 1:1 DNAzyme: mRNA reaction was carried 
out in Buffer 2 (150 mM NaCl, 2 mM MgCl2, 50 mM Tris-HCl), Buffer 4 (60 mM NaCl, 2 mM 
MgCl2, 50 mM Tris-HCl), and Buffer 6 (60 mM NaCl, 20 mM MgCl2, 15 mM Tris-HCl) to 
compare DNAzyme efficacy in various salts. Oligonucleotides were stained by SYBR gold. 
Lanes 5, 7, and 9 show the presence of cleavage products of the mutant K-Ras mRNA produced 
after incubation for 60 minutes at 37°C in Buffers 2, 4, and 6. 
Effective cleavage ability of the thiolDZ is shown in Figure 2.6. The thiol bond is vital 
for the oligonucleotide to covalently bond to the SNP. Figure 2.6 displays the denaturing 
electrophoresis gel of the combination of 10-23 DNAzyme and its target K-Ras mRNA substrate 
reacted at three different times. The first two lanes are using the K-Ras DNAzyme to react with a 
TYE665 labeled K-RAS mRNA. Lanes 3-5 are using the thiol conjugated DNAzyme to react 
with a TYE665 labeled K-RAS mRNA.  A 1:1 DNAzyme: mRNA reaction was carried out in 
Buffer 4 (60 mM NaCl, 2 mM MgCl2, 50 mM Tris-HCl), chosen from Figure 2.2 as the best 
buffer to work with. Oligonucleotides were stained by SYBR gold. Images were taken of the 
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TYE665 labeled RNA and overlayed with the SYBRgold images in ImageJ. Lanes 2 and 5 show 
the presence of cleavage products of the mutant K-Ras mRNA produced after incubation for 60 
minutes at 37°C. Lane 4 shows the presence of cleavage products of the mutant K-Ras mRNA 
produced after incubation for 30 minutes at 37°C with a 2:1 ratio amount of DNAzyme:RNA 
 
Figure 2.5. Cleavage of mutant K-Ras DZ using a 1:1 ratio of DNAzyme: mRNA in 3 separate 
buffers at 37°C for 60 minutes (SYBR Gold stained -488nm laser & 520bp40 filter). Lane 1) 
KRAS RNA; Lane 2)KRAS DZ; Lane 3) Low Molecular Weight Ladder 10-100 nt; Lane 4) 1:1 
KRAS DZ; KRAS RNA in B2 for 0min; Lane 5) 1:1 KRAS DZ; KRAS RNA in B2 for 60min; 
Lane 6) 1:1 KRAS DZ; KRAS RNA in B4 for 0min; Lane 7) 1:1 KRAS DZ; KRAS RNA in B4 
for 60min; Lane 8) 1:1 KRAS DZ; KRAS RNA in B6 for 0min; and Lane 9) 1:1 KRAS DZ; 
KRAS RNA in B6 for 60min. Buffers: B2-150mM NaCl & 2 mM MgCl2;; B4-60mM NaCl & 2 
mM MgCl2; and B6-60mM NaCl & 20 mM MgCl2). 
 
41 
 
 
Figure 2.6. Cleavage of mutant ThiolK-RasDZ using a 1:1 ratio of DNAzyme: mRNA in 60mM 
NaCl & 2 mM MgCl2 at 37°C for 0, 30, and 60 minutes. Denaturing gel was used. 1% DTT was 
added to break any formation of disulfide bonds. 
 
Components of the KRAS DNAzyme construct were characterized to help the main goals 
of the whole project. Figure 2.7A shows the SNP-TAMRA DZ construct fully. ThiolDZ and PC 
DZ would take the place of the TAMRA DZ in the Figure 2.7A construct. UV-Vis spectroscopy 
was used to characterize the presence of silver and any oligonucleotide additions to silver.  
Figure 2.7B shows the presence of HPC SNPs with and without the DNAzyme added to it. There 
was no red shift seen at the normal absorbance of silver, which is approximately 420nm. Figure 
2.7C and 2.7D did show a red shift when the citrate SNP was compared to the functionalized 
SNP with TAMRA DZ.  
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Figure 2.7. Design of TAMRA DZ construct and UV-Vis spectroscopy for HPC and Citrate 
SNPs. A) SNP functionalized with TAMRA DZ (including thiol bond, photocleavable linker, 
and KRAS DNAzyme oligonucleotide), B) 200-700nm UV-Vis spectroscopy of HPC SNP, C) 
200-700nm UV-Vis spectroscopy of Citrate SNP, and D) Zoomed in view of 250-500nm UV-
Vis spectroscopy of Citrate SNP in C. 
 
Since the size of nanoparticles used for drug delivery entering the body is critically 
important, the SNPs were characterized using TEM.  Figure 2.8A shows the unfunctionalized 
citrate SNPs. Figure 2.8B shows the functionalized citrate SNP. Figure 2.8C shows the 
unfunctionalized HPC SNP. Figure 2.8D shows the functionalized HPC SNP.   
Determination of oligonucleotide concentration is essential in characterizing the 
DNAzyme surface coverage around the SNPs.  Figure 2.9 shows the standard curve established 
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for the TAMRA DZ oligonucleotide.  The best fit line was used for all Tamra Oligonucleotide 
samples following after this. 
 
Figure 2.8. TEM images of particles.  A) Citrate SNP, B) Citrate SNP functionalized with 
TAMRA DZ, C) HPC SNP, and D) HPC SNP functionalized with TAMRA DZ. 
 
Table 2.1 shows the characterization of unfunctionalized and functionalized citrate and 
HPC SNPs using TEM, DLS, Zeta potential, ICP-OES, TAMRA DZ concentration 
determination, and surface coverage. Table 2.1 shows an increase in diameter size based on TEM 
results when comparing the unfunctionalized SNPs versus the functionalized SNPs, which 
includes the TAMRA DZ oligonucleotide. Table 2.1 DLS results show an increase from 
unfunctionalized citrate SNPs versus functionalized citrate SNPs including TAMRA DZ.  
Unfunctionalized HPC SNPs DLS results are shown to be larger than functionalized HPC SNPs  
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Figure 2.9.Standard curve for TAMRA DZ to quantify surface coverage. 
and backfilled HPC SNPs. 1%vol Dithiothreitol (DTT) was added to the functionalized SNPs to 
remove the oligos from the outer silver surface.  Following oligonucleotide removal, the silver 
quickly agglomerated as displayed in an even higher increase detected by dynamic light 
scattering (DLS). Table 2.1 zeta potential results show negative numbers correlating to the 
negative charge on the oligonucleotides. The backfilled functionalized HPC SNPs are even more 
negative in charge compared to the unfunctionalized HPC SNPs. TAMRA DZ oligonucleotide 
concentrations were taken after being cleaved from citrate and HPC SNPs by DTT or UV. DTT 
always removes more oligonucleotide. Surface coverage of citrate and HPC SNPs were 
determined using previous methods reported by Qureshi et al(Qureshi, Monroe et al. 2013). 
Table 2.1 results show an increase in number of oligonucleotides present on the surface of citrate 
and HPC SNPs per 100µl of treated sample.   
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Table 2.1. Characterization of SNPs, functionalized SNPs, and oligonucleotide surface coverage 
 
Effective cleavage ability of the ThiolDZ and effective removal of the thiolDZ from SNP 
using DTT is shown in Figure 2.10.  The electrophoresis gel was used as an activity assay.  
Average pixel intensity normalized by background pixel intensity was measured using Image J.  
The average pixel intensity of the cut KRAS mRNA was divided by the average pixel intensity 
of the uncut KRAS mRNA.  Figure 2.10 lane 8 shows the bands produced after SNP-ThiolDZ 
was reacted with TYE665 KRAS mRNA for 60 minutes. ThiolDZ was removed from citrate 
SNPs using DTT. The quotient of average pixel intensity for the cut and uncut mRNA bands was 
0.68. Since the number was less than one, it was confirmed that there was more uncut mRNA 
than cut mRNA. Figure 2.10 lane 10 shows the bands produced after ThiolDZ was removed from 
citrate SNPs using DTT. ThiolDZ was reacted with TYE665 KRAS mRNA for 60 minutes. The 
quotient of average pixel intensity for the cut and uncut mRNA bands was 1.97. Since the 
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number was greater than one, it was confirmed that there was more cut mRNA than uncut 
mRNA.     
 
Figure 2.10. A) Overlay of 2 images (SYBR Gold stained -488nm laser & 520bp40 filter and 
TYE665-633nm laser & 670bp30). Cleavage of mutant ThiolK-RasDZ using a 1:1 ratio of 
DNAzyme: mRNA in 60mM NaCl & 2 mM MgCl2 at 37°C for 0 and 60 minutes. Functionalized 
citrate SNP samples had DTT and then RNA added or RNA and then DTT added. Denaturing 
gel was used. 1% DTT was added to the Citrate SNP for 2hrs and rocked at 37°C. Sample was 
centrifuged (3x, 7000RPM, 20min each) to remove SNPs.  B) Ratio of Uncut and Cut RNA 
compared to DNAzyme present.   
 
Effective cleavage ability of the PC DZ and photolysis of the nitrophenylethyl internal 
photocleavable linker are shown in Figure 2.11. The focus of Figure 2.11 is lanes 3-6. Lane 3 
and 5 were photolysed, and lanes 4 and 6 were not photolysed. SNP-PC DZ and PC DZ were 
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reacted with TYE665 KRAS mRNA for 5 and 30 minutes. The quotient of average pixel 
intensity for the cut and uncut mRNA bands for lanes 3 and 4 were 0.76 and 0.75. Since the 
number was less than one, it was confirmed that there was more uncut mRNA than cut mRNA. 
The quotient of average pixel intensity for the cut and uncut mRNA bands for lanes 5and 6 were 
1.25 and 1.22. Since the number was greater than one, it was confirmed that there was more cut 
mRNA than uncut mRNA. During a time when several experiments were run in parallel, analysis 
of the results suggested that the HPC SNPs would need to be backfilled for better cleavage 
activity in the assay. Too much of the DNAzyme is cleaving KRAS mRNA, even when the 
oligonucleotide is not released from the SNP. 
 
Figure 2.11. Flashed and Unflashed samples. Cleavage of mutant ThiolK-RasDZ using a 1:1 
ratio of DNAzyme: mRNA in 60mM NaCl & 2 mM MgCl2 at 37°C for 0 , 30, and 60 minutes on 
and off Citrate SNPs. Denaturing gel was used. 1% DTT was added to the Citrate SNP for 2hrs 
and rocked at 37°C. Sample was centrifuged (3x, 7000RPM, 20min each) to remove SNPs. 
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Effective cleavage ability of the TAMRA DZ, photolysis of the nitrophenylethyl internal 
photocleavable linker, and enzymatic protection of the oligonucleotide are shown in Figure 2.12.  
The focus of Figure 2.12 is lanes 8-10. SNP-PC DZ was reacted with DNase I for 0,5, and 15 
minutes. Several bands are visualized at all three time periods. Again, analysis of the results 
suggested that the HPC SNPs would need to be backfilled for better protection from enzymatic 
cleavage.  
 
Figure 2.12. DNase I cleavage of unprotected mutant K-Ras DZ and protected HPC SNP/PC DZ 
for reactions of 0,5, and 15 minutes in buffers rocking at 37°C (SYBR Gold stained -488nm laser 
& 520bp40 filter). Lane 1) Low Molecular Weight Ladder 10-100 nt; Lane 2, 3, and 4) KRAS 
DZ reacting with DNase I for 0,5, and 15 minutes; Lanes 5,6,and 7) PC KRAS DZ reacting with 
DNase I for 0,5, and 15 minutes; Lanes 8,9, and 10) SNP/ PC KRAS DZ reacting with DNase I 
for 0, 5, and 15 minutes. 1% DTT was added to the SNP for 2hrs and rocked at 37°C. 
Supernatant was collected after sample was centrifuged (3x, 7000RPM, 20min each) to remove 
SNPs. 
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Overall, the DNAzyme on the HPC SNPs required less cleavage of the KRAS mRNA 
and offered better protection from enzymatic cleavage in the tethered form.  This finding 
prompted the backfilling of HPC SNPs with one tenth the concentration of DNAzyme using 11- 
Mercaptoundecanoic acid.  Increased optimization of the coverage of DNAzyme oligonucleotide 
surrounding the SNP surface is shown in Figure 2.13. Table 2.1 results show that an increase in 
oligonucleotide surface coverage took place with the backfilled particles.  
 
Figure 2.13. TEM images of particles.  A) HPC SNP functionalized with TAMRA DZ and 
backfilled with 11-Mercaptoundecanoic acid for 2 hrs, B) HPC SNP functionalized with 
TAMRA DZ DZ and backfilled with 11-Mercaptoundecanoic acid for 2 hrs, C) HPC SNP 
functionalized with TAMRA DZ DZ and backfilled with 11-Mercaptoundecanoic acid for 24 
hrs, and D) HPC SNP functionalized with TAMRA DZ DZ and backfilled with 11-
Mercaptoundecanoic acid for 24 hrs. Scale bar is 100nm. 
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2.4 CONCLUSIONS 
The construction of a SNP-10-23 DNAzyme oligonucleotide conjugate is significant in 
several regards to current developments in photoactivated gene regulation. An inducible 
DNAzyme oligonucleotide that could be delivered to cells via SNP transport by stable and 
consistent particles is the critical point made by this project’s goals. While citrate-stabilized SNP 
were first utilized in the project, hydroxypropylcellulose (HPC)-stabilized particles were chosen 
for future cell studies since they were highly biocompatible, aggregated less than the citrate 
SNPs, and were more shelf-stable. Gel electrophoresis was used to demonstrate effective 
cleavage activity in the various forms of the KRAS DNAzyme, which included thiol, 
photocleavable linker, and TAMRA modified forms, all showing similar degradation of RNA 
similar to the original unmodified DNAzyme.  Similarly, gel electrophoresis was used to show 
that DNAzyme tethered to the SNP showed less activity than when photoreleased from the 
conjugate.  DNAse did not digest SNP-tethered DNAzymes as quickly as DNAzymes free in 
solution, indicating protection of the nucleic acids in the conjugated form. 
The next directions of the project involved evaluation the photoactivation of the construct 
in cells, hypothesized to sensitize mutant KRAS positive cells to chemotherapeutic, yet not 
affecting non-mutant containing KRAS cells. An aim motivating the use of this SNP construct is 
to cause less collateral damage due to off-target effects of medicines in unintended tissues. This 
gene-regulated approach could improve current chemotherapy efficacy, allowing use of lower 
concentrations of drug and thereby improving patient tolerance as well as targeted cancer cell 
necrosis. 
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CHAPTER 3. CHARACTERIZATION OF CELLULAR RESPONSES TO 
SNP-DNAZYME AND DOXORUBICIN 
 
3.1 INTRODUCTION 
 
In this portion of the project, the silver nanoparticle (SNP) conjugated with DNAzyme 
was evaluated in cells as a potential cancer treatment.  To increase cancer cell sensitivity to the 
chemotherapeutic doxorubicin, cells are treated with the SNP-DNAzyme construct, which when 
combined with photoactivation, permits mutant KRAS mRNA cleavage and induction of 
apoptosis in cancer cells. The photocleavable construct permits spatiotemporal targeting, offering 
another level of control in increasing cell death only in those cells exposed to light.  Paclitaxel 
was the initially chosen as the chemotherapeutic drug choice for this project, but was decided 
against given that it targets the same microtubule network pathway as does the K-Ras regulatory 
system (Thissen, Gross et al. 1997, Chen, Otto et al. 2000). Doxorubicin is an excellent 
alternative chemotherapeutic agent since it functions by intercalating DNA. The drug is used in 
the treatment of several cancers including breast and colon cancer (Reviewed by (Khasraw, Bell 
et al. 2012)). Doxorubicin is an anthracycline antibiotic derived from the bacterial species 
Streptomyces and further modified using a chemical semisynthesis (Guilfoile and Hutchinson 
1991) (Reviewed by (Aubel-Sadron and Londos-Gagliardi 1984)). As a chemotherapeutic, it is 
delivered intraveneously liposome-encapsulated or as a hydrochloride salt (Reviewed 
by(Gabizon, Shmeeda et al. 2003) (Travis, Curtis et al. 1991, Khasraw, Bell et al. 2012)).  
K-RAS is an oncogene which is essential for regulating cell division (Reviewed 
by(Dahabreh, Terasawa et al. 2011)). According to oncologists, the most common KRAS 
mutation occurs on codons 12 and 13, while the more rare forms of KRAS mutations affect 
codons 61 and 146 (Reviewed by (Allegra, Jessup et al. 2009)). Wild type cell lines have normal 
conversions between on and off in normal KRAS genes.  On the other hand, mutant cell lines are 
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continuously dividing due to the inactivation of this essential cellular division toggle switch. 
These mutant signal transduction pathway proteins are major causes for pancreatic, colorectal, 
endometrial, biliary tract, lung, and cervical cancers (Reviewed by (Yu, Wang et al. 2009)).  
Another issue with the KRAS mutation is that not all therapies are recommended to fix this 
mutation. Specifically, Allegra et al. did not recommend the use of anti-EGFR monoclonal 
antibody therapy (Reviewed by (Allegra, Jessup et al. 2009, Dahabreh, Terasawa et al. 2011)). 
Yu et al. suggest a treatment of DNAzyme and doxorubicin as alternative method of 
treatment(Yu, Wang et al. 2009).  Our project suggests a step further with the addition of a silver 
nanoparticle carrier for intracellular delivery and spatial control of cleavage of mutant KRAS 
mRNA. The cell lines evaluated in this project include control lines, HT29 and HEK293, and the 
mutant K-RAS-positive cancer lines SW480 and SW620. The breast cancer cell lines include a 
control line, MCF-7, and the mutant KRAS-positive line, MDA-MB-231. 
In this portion of this project, the delivery of SNP-DNAzyme and doxorubicin-HCl was 
staggered, allowing the DNAzyme to degrade KRAS mRNA, thus sensitizing the cell to 
doxorubicin before its application. SNP-DNAzyme is delivered and photoactivated in the 
corresponding colon and breast cancer cell lines 24 hours prior to treatment with doxorubicin. 
Photoreleasing the DNAzyme from the SNP and initiating gene-regulating of KRAS mRNA is 
thought to enhance the sensitivity of the colon and breast cancer cells to doxorubicin, and 
demonstrate the potential of this therapy. 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
DNAzyme and RNA materials 
Silver nanoparticles were functionalized with thiol-modified KRAS DNAzymes ordered 
from Integrated DNA Technologies (5'- CTA CGC CAA GGC TAG CTA CAA CGA AGC 
TCC AAC T /3ThioMC3-D/ -3', IDT, Coralville, IA) or Trilink Biotechnologies (5' (TAMRA) 
(C6-NH) CTA CGC CAA GGC TAG CTA CAA CGA AGC TCC AAC T (PC Spacer) T (C3-S-
S-C3) 3', San Diego, CA) based on DNAzyme reported by Yu et al.(Yu, Wang et al. 2009). 
KRAS mRNA were ordered from Integrated DNA Technologies (5'- rArGrU rUrGrG rArGrC 
rUrGrU rUrGrG rCrGrU rArG -3' or 5'-/5TYE665/rArGrU rUrGrG rArGrC rUrGrU rUrGrG 
rCrGrU rArG -3', IDT, Coralville, IA) based on complementary sequence to DNAzyme. 
Turbofect transfection reagent was purchased from Thermo Fisher Scientific (Rochester, NY). 
Citrate and HPC Silver Nanoparticle Oligonucleotide Materials 
Silver nitrate (Sigma Ultra >99%) and sodium citrate were purchased from Sigma 
Aldrich (St. Louis, MO). PTFE resin-coated magnetic stirring bars were purchased from VWR 
(West Chester, PA). 100 mL Glass syringes used to dispense sodium citrate dropwise to reduce 
silver nitrate in solution were purchased from KD scientific (Holliston, MA). All other glassware 
was purchased through Fisher Scientific (Pittsburgh, PA). Hydroxypropyl cellulose SNP, 
SmartSilver
TM
AS, was purchased from NanoHorizons Inc (Bellefonte, PA). Silver nanoparticles 
were functionalized with thiol-modified miRNA 125b or KRAS DNAzymes ordered from 
Integrated DNA Technologies (IDT, Coralville, IA) or Trilink Biotechnologies (San Diego, CA). 
2M Tris-NaCl buffer (pH 8.0) was made up from Biotechnology grade Tris (Amresco Inc, Solon, 
OH) and sodium chloride (Fischer Scientific, Pittsburgh, PA). 11-Mercaptoundecanoic acid was 
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obtained from Sigma Aldrich (St. Louis, MO). 16% paraformaldehyde was obtained from 
Electron Microscopy Sciences (Hatfield, PA). 
Cell Materials 
Cell studies have been performed on 3T3 (Mouse fibroblast cells, American Type Culture 
Collection), HT29 (Human colon adenocarcinoma grade II cells, American Type Culture 
Collection), SW620 (Human colon adenocarcinoma grade II cells, American Type Culture 
Collection), NIH/3T3 (Mouse fibroblast cells, American Type Culture Collection), HEK293 
(Human kidney epithelial  cells, American Type Culture Collection), SW480 (Human colon 
adenocarcinoma grade II cells, American Type Culture Collection), MCF-7 (Human mammary 
gland/breast cancer cells, American Type Culture Collection), and MDA-MB-231 cells (Human 
mammary gland/breast cancer cells, American Type Culture Collection). All cells are maintained 
in 25 cm
2
 flasks (BD Falcon, Franklin Lakes, NJ) and incubated at 37
◦
C in a humidified 5% CO2 
environment. Dulbecco’s Modified Eagle’s Medium (DMEM); Dulbecco’s Phosphate-Buffered 
Saline (DPBS); Fetal Bovine Serum (FBS); Calf serum; GlutaMAX™; Sodium Pyruvate 
(NaPyr); Non-Essential Amino Acids (NEAA); HEPES buffer; Supplement of Insulin, 
Transferrin and Selenium (ITS); and 0.25% Trypsin were purchased from Fischer Scientific 
(Pittsburgh,PA). Dulbecco’s Modified Eagle’s Medium-High glucose (DMEMHG) and 
Minimum Essential Medium (MEM) were purchased from GIBCO
TM
 via Thermo Fisher 
Scientific (Rochester, NY). 
3T3, HT29, SW620, HEK293, and SW480 cells were originally grown in 5 mL of 
Dulbecco’s Modified Eagle’s medium-reduced serum (DMEM-RS, Fischer Scientific, 
Pittsburgh, PA) supplemented with 10% fetal bovine serum (FBS, Fischer Scientific, Pittsburgh, 
PA). NIH/3T3 cells are grown in 5 mL of DMEMHG (Thermo Fischer Scientific, Rochester, 
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NY) supplemented with 10% calf serum, 2mM glutaMAX™, 1mM NaPyr, 1X NEAA, and 
10mM HEPES buffer (Fischer Scientific, Pittsburgh, PA). HEK293 and SW480 cells are grown 
in 5 mL of MEM (Thermo Fischer Scientific, Rochester, NY) supplemented with 10% FBS, 
2mM glutaMAX™, 1mM NaPyr, and 1X NEAA (Fischer Scientific, Pittsburgh, PA). MCF-7 
cells are grown in 5 mL of DMEMHG (Thermo Fischer Scientific, Rochester, NY) 
supplemented with 10% FBS, 2mM glutaMAX™, 1mM NaPyr, 1X NEAA, 10mM HEPES 
buffer, and 1X ITS (Fischer Scientific, Pittsburgh, PA). 
MTS, Alamar Blue, and Flow Cytometry Assays 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) was purchased 
from Promega
 
(Madison, WI). Alamar Blue® Cell Viability Reagent was purchased from 
Invitrogen
TM
 by Thermo Fisher Scientific (Rochester, NY). Sytox® Red dead cell stain was 
purchased from Molecular Probes
TM
 by Thermo Fisher Scientific (Rochester, NY). Pure ethanol 
was purchased from PHARMCO-AAPER (CT), and 3% hydrogen peroxide was purchased from 
Humco (Texarkana,TX). Doxorubicin hydrochloride was purchased from MP Biomedicals. All 
solvents purchased were of analytical grade. 
3.2.2 Methods 
 
Ex vivo Photocleavage of SNP-DNAzyme Oligonucleotide 
Cells were seeded in 96, 48, 24, or 12 well plates (2,500cells/0.32cm
2
) and allowed to 
incubate for 24 hours in appropriate media at 37°C prior to SNP, SNP-DNAzyme 
oligonucleotide conjugate, or DNAzyme treatment in a cell media volume (100 µl /96 wells, 600 
µl/12 wells). DNAzyme was added with Turbofect transfection reagent; various amounts of 
SNP-DNAzyme oligonucleotide conjugates (54pM silver, ~700 oligos:1 SNP) were added to the 
wells. Treated cells were incubated at 37°C in a CO2 incubator for 16 hours followed by flashing 
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for 21 seconds at 365nm (12 J/cm
2
) using a GreenSpot system (American Ultraviolet, Lebanon, 
IN). The system has a 100–watt, pressurized mercury lamp with a 5mm x 1000mm light guide, 
which has a peak spectral output of 365nm. The lamp has a fluence of 186.4 mW/cm2 when used 
with the short bandpass filter (1.5mm thick, 2.4mm diameter SWP–2502U–400, Lambda 
Research Optics, CA) and the long bandpass filter (Newport Corporation, Irvine, CA).  Together 
these filters pass only 320-400nm light, which is appropriate for photocleavage of the 
nitrobenzyul which has peak absorption at 365nm.  Several controls were performed, including 
cells not exposed to UV light yet injected with 5µl of SNP-DNAzyme oligonucleotide 
conjugates, as well as the addition of doxorubicin with or without ultraviolet light and with or 
without SNP-DNAzyme conjugates. 
Flow Cytometry Assay: Cytotoxicity of Treatment on Designated Cells 
3T3, HT29, and SW620 cells were maintained in 25 cm
2
 flasks (BD Falcon, Franklin 
Lakes, NJ) with 5 ml of Dulbecco’s Modified Eagle’s medium-reduced serum (DMEM-RS) 
supplemented with 10% FBS and incubated at 37ºC in 5% CO2. NIH/3T3 cells are grown in 5 
mL of DMEMHG supplemented with 10% calf serum, 2mM glutaMAX™, 1mM NaPyr, 1X 
NEAA, and 10mM HEPES buffer and incubated at 37ºC in 5% CO2. HEK293 and SW480 cells 
are grown in 5 mL of MEM supplemented with 10% FBS, 2mM glutaMAX™, 1mM NaPyr, and 
1X NEAA and incubated at 37ºC in 5% CO2. MCF-7 cells are grown in 5 mL of DMEMHG 
supplemented with 10% FBS, 2mM glutaMAX™, 1mM NaPyr, 1X NEAA, 10mM HEPES 
buffer, and 1X ITS and incubated at 37ºC in 5% CO2. The cells were plated at a density of 3x10
4
 
cells/well in 12-well culture plates (BD Falcon, Franklin Lakes, NJ) and were allowed to adhere 
and grow for 24 hours prior to treatment.  Samples treated with silver or SNP-conjugated 
oligonucleotides were incubated at 37ºC in 5% CO2 for 16 hours or 6 days; samples treated with 
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12 J/cm
2
 ultraviolet light (UV) were incubated at 37ºC in 5% CO2 for 24 hours or 6 days; 
samples treated with varying amounts of doxorubicin (DOX) were incubated at 37ºC in 5% CO2 
for 48 hours or 6 days; samples treated with silver or SNP-conjugated oligonucleotides, UV, and 
DOX were incubated at 37ºC in 5% CO2 for 6 days. 6 day experiments followed the method 
reported by Yu et al (Yu, Wang et al. 2009).  For a necrotic control, cells were incubated for 24 
hours with 4µl of 3% hydrogen peroxide. After treatment, non-adhered cells were washed with 1 
ml D-PBS and collected while adhered cells were harvested by trypsinization (0.25% Trypsin). 
The cells were pooled together and centrifuged at 1800 rpm to obtain cell pellet. Cells were re-
suspended in 1 ml D-PBS and stained with ending concentration of 5nM Sytox Red for 15 
minutes in the dark, then centrifuged and fixed in 250 ul of 1% paraformaldehyde (PFA) solution 
in D-PBS for flow cytometric analysis of viability with a BD FACS Calibur cytometer (Franklin 
Lakes, NJ). For each sample, scatter and fluorescent data was collected for 1,000-30,000 cell 
events using Cellquest pro (BD Biosciences, San Jose, CA) and former analyzed using WinMDI 
2.8 software (by Dr M Dietrich, LSUHSC Veterinary School, Baton Rouge, LA). 
MTS Assay: Cytotoxicity of Treatment on Designated Cells 
 
3T3, HEK293, and SW480 cells were maintained in 25 cm
2
 flasks (BD Falcon, Franklin 
Lakes, NJ) with 5 ml of Dulbecco’s Modified Eagle’s medium-reduced serum (DMEM-RS) 
supplemented with 10% fetal bovine serum (FBS) and incubated at 37ºC in 5% CO2. The cells 
were plated at a density of 2.5x10
-3
 cells/well in 96-well culture plates (BD Falcon, Franklin 
Lakes, NJ) and were allowed to adhere and grow for 24 hours before being injected with various 
treatments for appropriate corresponding times. Samples treated with silver or SNP-conjugated 
oligonucleotides were incubated at 37ºC in 5% CO2 for 16 hours; samples treated with 12 J/cm
2
 
ultraviolet light (UV) were incubated at 37ºC in 5% CO2 for 24 hours; samples treated with 
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varying amounts of doxorubicin (DOX) were incubated at 37ºC in 5% CO
2
 for 48 hours; and 
samples treated with silver or SNP-conjugated oligonucleotides, UV, and DOX were incubated 
at 37ºC in 5% CO2 for 6 days. 6 day experiments followed the method reported by Yu et al (Yu, 
Wang et al. 2009). For a necrotic control, cells were incubated for 4 hours with 4µl of hydrogen 
peroxide or 100µl 70% ethanol. After appropriate treatment time, 20µl of pooled 20:1 MTS/PMS 
solution were added to each treated well. After 4 hours of incubation at 37ºC in 5% CO2, the 
absorbance at 490nm was recorded using a Wallac 1420 VICTOR2™ plate reader (Perkin 
Elmer, Shelton, CT). 
Alamar Blue Assay: Cytotoxicity of Treatment on Designated Cells 
 
3T3cells were maintained in 25 cm
2
 flasks (BD Falcon, Franklin Lakes, NJ) with 5 ml of 
DMEM supplemented with 10% FBS and incubated at 37ºC in 5% CO2. NIH/3T3 cells are 
grown in 5 mL of DMEMHG supplemented with 10% calf serum, 2mM glutaMAX™, 1mM 
NaPyr, 1X NEAA, and 10mM HEPES buffer and incubated at 37ºC in 5% CO2. HEK293 and 
SW480 cells are grown in 5 mL of MEM supplemented with 10% FBS, 2mM glutaMAX™, 
1mM NaPyr, and 1X NEAA and incubated at 37ºC in 5% CO2. The cells were plated at a density 
of 2.5x10
-3
 cells/well in 96-well culture plates (BD Falcon, Franklin Lakes, NJ) and were 
allowed to adhere and grow for 24 h prior to injecting with various treatments for appropriate 
corresponding times. Samples treated with silver or SNP-conjugated oligonucleotides were 
incubated at 37ºC in 5% CO2 for 16 hours or 6 days; samples treated with 12 J/cm
2
 ultraviolet 
light (UV) were incubated at 37ºC in 5% CO2 for 24 hours or 6 days; samples treated with 
varying amounts of doxorubicin (DOX) were incubated at 37ºC in 5% CO2 for 48 hours or 6 
days; samples treated with silver or SNP-conjugated oligonucleotides, UV, and DOX were 
incubated at 37ºC in 5% CO2 for 6 days. 6 day experiments followed the method reported by Yu 
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et al (Yu, Wang et al. 2009). For a necrotic control, cells were incubated for 24 hours with 4µl 
3% hydrogen peroxide, 100µl 70% ethanol, or 100µl 100% ethanol. After appropriate treatment 
time, 100µl of pooled 10:1 corresponding media/ alamarBlue® dye solution were added to each 
treated well. After 4 hours of incubation at 37ºC in 5% CO2, the fluorescence with excitation and 
emission 531nm/ 595nm nm was recorded using a Wallac 1420 VICTOR2™ plate reader (Perkin 
Elmer, Shelton, CT). 
3.3 RESULTS AND DISCUSSION 
 The goals of this portion of the project include the determination of cellular thresholds to 
photoactivating doses of UV light, doxorubicin dose-response thresholds, cellular responses to 
treatment with DNAzyme alone and with synergistic doses of DNAzyme, UV, and doxorubicin.  
The system of cells used for proof of concept is crucial to show the actual effect of the treatment 
in comparison to the negative control. Three sets of cells were analyzed using either a flow 
cytometry viability assay, a spectrophotometric MTS assay, a fluorescence-based alamar blue 
assay, or a combination of these assays.  In each group, three cell lines were used: a cell line 
containing the wild type KRAS gene, a cell line containing the mutant KRAS gene, and one cell 
line not containing either wild type or mutant KRAS gene. 
3.3.1 KRAS DNAzyme Experiments 
KRAS DZ Cytotoxicity Assay 
Because colon cancer was shown in the literature to respond to KRAS-targeted therapies, 
the first two sets of wild type and mutant cell lines in this project included colon cancer cell 
lines. Set 1 included the negative control wild type KRAS line (HT29), the mutant KRAS line 
(SW620), and the negative control line (3T3). Figure 3.1 shows the ineffectiveness of 5 µg (8.3 
mM) of KRAS DNAzyme on the SW620 colon cancer cells or 3T3 control fibroblast cells after 
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16 hours. Analysis of the HT29 cells treated with the same degrees of DNAzyme concentration 
was not reliable since positive control live cells were not effectively living (HT29 cells flow 
cytometry data was not shown). Yu et al. found an effective dose in their study at approximately 
8.0mM DNAzyme using mutant KRAS gene SW480 and wild type KRAS gene HEK293 cell 
lines. Thus, the SW620 and HT29 cells were replaced with a new set of SW480 and HEK293 
cell lines to appropriately compare the treatment of SNP-TAMRA DZ conjugates to that of 
DNAzyme alone. 
 
Figure 3.1.  KRAS DZ Cytotoxicity Assay using Flow Cytometry. 
 
Treatment Plan Protocol 
Set 2 included the negative control wild type KRAS line (HEK293), the mutant KRAS 
line (SW480), and the negative control line (3T3). Figure 3.2 shows the 5 day process used for 
the following results shown.  There were several experiments testing the effective dosage of 
DNAzyme given to cells after 16 hours, the effective dosage of UV given to cells after 24 hours, 
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and the effective dosage of Doxorubicin given to cells after 48 hours. However, the full 
synergistic effect of all components could not be compared until all cells and their controls went 
through the 5 day process. Cells are seeded on Day 0. A treatment of SNP, DNAzyme, or SNP-
DNAzyme conjugate is delivered on Day 1 (16 hours later). A dosage of UV light is delivered to 
untreated or treated cells on Day 2 (24 hours later). A dosage of doxorubicin is delivered to 
untreated or treated cells on Day 3 (48 hours later). The treatment time for oligonucleotide 
construct delivery and UV dosage was determined from the method reported by Brown et al.. 
The treatment time for doxorubicin delivery was determined from the method reported by Yu et 
al. After the 5 day process, positive results would show the death of SW480 cells, tolerable 
amount of mortality of HEK293 cells, and viable negative control 3T3 cells. 
 
Figure 3.2. 5 day plan of seeding cells, treated with SNP conjugate samples, UV, and 
Doxorubicin. 
Day 3:Add 1 µM 
Dox for 48 hrs
Day 5:Read assay
Day 2: Add 3min 
UV for 24 hrs
Day 1: Add 
SNP/DZ for 
16 hrs
Day 0: Seed cells 
for 24 hrs
SW480
3T3
HEK293
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UV and Doxorubicin Cytotoxicity Assay 
Doses of UV light, SNP-DNAzyme, and doxorubicin were chosen based on results from 
individual experiments testing the effective dosage of DNAzyme given to cells after 16 hours, 
the effective dosage of UV given to cells after 24 hours, and the effective dosage of Doxorubicin 
given to cells after 48 hours. The effective dose of UV given to cells after 24 hours was 12 J/cm
2
 
(optimized dosage data not shown). The effective dosage of Doxorubicin given to cells after 48 
hours was 1 µM Doxorubicin (optimized dosage data not shown).  Figure 3.3 shows the 5 day 
treatment response of cells to controls of 12 J/cm
2  
UV, 1 µM Doxorubicin, combined 12 J/cm
2 
UV and 1 µM Doxorubicin, and 8.0 mM dosage of 2’omethyl KRAS DNAzyme conjugated with 
Turbofect. Figure 3.3 lane 3 shows the SW480 colon cancer cells were less viable than the 3T3 
control fibroblast cells with the 12 J/cm
2 
UV. Figure 3.3 lane 4 shows the SW480 colon cancer 
cells and the 3T3 control fibroblast cells had high viability with the 1 µM Doxorubicin dosage.  
Figure 3.3 lane 5 shows the SW480 colon cancer cells and the 3T3 control fibroblast cells had 
high viability with the 12 J/cm
2 
UV and 1 µM Doxorubicin dosage. Figure 3.3 lane 6 shows the 
SW480 colon cancer cells and the 3T3 control fibroblast cells had high viability with the SNP 
dosage (1x, same amount of silver given in SNP-DNAzyme construct dosage). Figure 3.3 lane 8 
shows the SW480 colon cancer cells and the 3T3 control fibroblast cells were less viable with 
the 8.0 mM 2’omethyl DNAzyme conjugated to turbofect dosage. Analysis of the HEK293 cells 
treated with the same treatments was not reliable since positive control live cells were not 
effectively surviving (HEK293 cells MTS and Alamar Blue assays data was not shown). 
Analysis of the results showed positive feedback from the synergistic treatment of UV and 
Doxorubicin dosages, thus the full treatment of SNP-DNAzyme constructs were attempted. 
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Figure 3.3. Results from control treatments of SW480 and 3T3 cells for 5 days using an alamar 
blue assay. Lane 1: positive control live cells; Lane 2: negative control dead cells; Lane 3:12 
J/cm
2
 UV dosage; Lane 4: 1 µM Doxorubicin dosage; Lane 5: 12 J/cm
2 
UV and 1 µM 
Doxorubicin dosage; Lane 6:SNP dosage (1x, corresponding to silver present in 1x dosage of 
SNP-TAMRA DNAzyme construct); Lane 7: SNP-TAMRA DNAzyme construct dosage (1x); 
and Lane 8: 8.0 mM 2’omethyl DNAzyme conjugated with Turbofect. 
 
SNP-DNAzyme Construct Cytotoxicity Assay 
For the 5 experimental protocol, 12 J/cm
2
 UV and 1µM doxorubicin dosages were given 
to SW480 colon cancer cells. A comparison of samples that were and were not photoexposed 
was the focus of Figure 3.4. Figure 3.4 lanes 7-10 show the SW480 cells treated with SNP-
DNAzyme construct, photoexposed, and doxorubicin treated were less viable than the SW480 
colon cancer cells treated with SNP-DNAzyme construct and doxorubicin but not photoexposed. 
These results were encouraging; however, the cells treated only with 12 J/cm
2 
UV were not 
highly viable (Figure 3.4 lane 4). This varies significantly from results previously shown. Since 
one of the negative controls showed inconclusive results, further evaluation was deemed 
necessary.   
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Figure 3.4. Results from control treatments of SW480 for 5 days using an alamar blue assay. 
Lane 1: positive control live cells; Lane 2: negative control dead cells; Lane 3: 1 µM 
Doxorubicin dosage; Lane 4: 12 J/cm
2 
UV and 1 µM Doxorubicin dosage; Lane 5:SNP dosage 
(1x, corresponding to silver present in 1x dosage of SNP-TAMRA DNAzyme construct); Lane 
6:SNP dosage (1x, corresponding to silver present in 1x dosage of SNP-TAMRA DNAzyme 
construct) and 1 µM Doxorubicin; Lane 7: SNP-TAMRA DNAzyme construct dosage (0.13x); 
Lane 8: SNP-TAMRA DNAzyme construct dosage (0.25x); Lane 9: SNP-TAMRA DNAzyme 
construct dosage (0.5x); and Lane 10: SNP-TAMRA DNAzyme construct dosage (1x). 
Concentration of sample was 0.10µg/100µl. 
 
SNP-DNAzyme Backfilled with 11-Mercaptoundecanic Acid Construct Cytotoxicity Assay 
Since one of the objectives of this project was to have greater protection of the 
DNAzymes from endonucleases, the SNP-DNAzyme constructs were backfilled with 11-
Mercaptoundecanoic acid.  Backfilled SNP-DNAzyme constructs were also tried as treatments in 
SW480 cells. Since several experiments ran concurrently, some of the data results shown in 
Figure 3.5 were also shown in Figure 3.4. For this 5 day experimental protocol in Figure 3.5, 12 
J/cm
2
 UV and 1µM Doxorubicin dosages were used for the following experiment using SW480 
cells. A comparison of backfilled and not backfilled samples that were and were not 
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photoexposed was the focus of Figure 3.5. Figure 3.5 lanes 5-8 show the SW480 colon cancer 
cells treated with SNP-DNAzyme construct, photoexposed, and doxorubicin treated were less 
viable than the SW480 colon cancer cells treated with SNP-DNAzyme construct and doxorubicin 
but not photoexposed. Figure 3.5 lanes 9-12 show the SW480 colon cancer cells treated with 
backfilled SNP-DNAzyme construct, photoexposed, and doxorubicin treated were less viable 
than the SW480 colon cancer cells treated with SNP-DNAzyme construct and doxorubicin but 
not photoexposed. Again, these results are promising since the treatment quantitatively has a 
significant difference to the non-photoexposed samples in both the backfilled and non-backfilled 
samples. However, Figure 3.5 lane 4 shows the SW480 colon cancer cells photoexposed with 12 
J/cm
2 
UV were not largely viable. This varies significantly from results previously shown. Since 
one of the negative controls in this experiment also showed inconclusive results, it was 
concluded that further evaluation was necessary. 
SW480 Positive and Negative Control Cytotoxicity Assay 
Since one of the objectives of this project was to establish an appropriate cell system to 
show the proof of concept of this drug-targeted gene therapy, it became crucial to check the 
viability of the control treatments using flow cytometry rather than bulk cell well measurements 
as done previously which showed unreliable control results (Figures 3.4 and 3.5). Another 
experiment was run on live and dead controls alone that showed similar problems with cell 
counts being entirely too low; samples were unsuccessfully treated to different processing 
techniques to improve cell counts (data not shown). Figure 3.6 shows the number of cell events 
collected at the top of the bars. Clearly, the data is questionable when the dead control shows 
100% viability with a 4,000 cell events count, as after 5 days in this experimental protocol, the 
number of cells should be greater than 50,000. Also concerning was the difficulty in 
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Figure 3.5. Results from control treatments of SW480 for 5 days using an alamar blue assay. 
Lane 1: positive control live cells; Lane 2: negative control dead cells; Lane 3: 1 µM 
Doxorubicin dosage; Lane 4: 12 J/cm
2 
UV and 1 µM Doxorubicin dosage; Lane 5: SNP-
TAMRA DNAzyme construct dosage (0.13x); Lane 6: SNP-TAMRA DNAzyme construct 
dosage (0.25x); Lane 7: SNP-TAMRA DNAzyme construct dosage (0.5x); Lane 8: SNP-
TAMRA DNAzyme construct dosage (1x). DNAzyme concentration of sample from Lanes 5-8 
was 0.10µg/100µl. Lane 9: Dosage of SNP-TAMRA DNAzyme construct backfilled with 11-
mercaptoundecanoic acid (0.13x); Lane 10: Dosage of SNP-TAMRA DNAzyme construct 
backfilled with 11-mercaptoundecanoic acid (0.25x); Lane 11: Dosage of SNP-TAMRA 
DNAzyme construct backfilled with 11-mercaptoundecanoic acid (0.5x); Lane 12: Dosage of 
SNP-TAMRA DNAzyme construct backfilled with 11-mercaptoundecanoic acid (1x). 
DNAzyme concentration of sample from Lanes 9-12 was 0.13µg/100µl. 
 
inducing death in dead-control cells.  Treatments such as 70% ethanol, 100% ethanol, and 
hydrogen peroxide were used at different times to treat these dead control samples. In addition to 
having a difficult time collecting cells for these dead control samples, data collected for the 
treated samples was also problematic. Numbers of cell events collected varied significantly and 
could not be reliably trusted for accurate interpretations of the SNP-DNAzyme effects of cancer 
cell viability. 
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Figure 3.6. Results from treatments of SW480 for 5 days using a flow cytometry assay. Lane 1: 
positive control live cells; Lane 2: negative control dead cells; Lane 3: 12 J/cm
2 
UV and 1 µM 
Doxorubicin dosage; Lane 4: Backfilled SNP-TAMRA DNAzyme construct 12 J/cm
2 
UV and 1 
µM Doxorubicin dosage, (1x); and Lane 5: Backfilled SNP-TAMRA DNAzyme construct 
dosage. 
 
Evaluation of SNP-DNAzyme in MCF-7 and MDA-MB-231 Cells 
Since the colon cancer cells were not appropriate systems for proof of concept, MCF-7 
and MDA-MB-231 breast cancer cells were evaluated for treatment with the SNP-DNAzyme 
therapy. These experiments, grouped as “Set 3”, included the negative control wild type RAS 
line (MCF-7) and the mutant KRAS line (MDA-MB-231)(Ikediobi, Davies et al. 2006, Adams, 
Deremer et al. 2010).  This set of cells was used because it contains a KRAS mutation. However, 
in the late stages of the project it was noted that MDA-MB-231 cells actually contain the KRAS 
mutant gene on the 13
th
 codon instead of on the 12
th
 codon similar to the mutation in the SW480 
and SW620 cells (ATCC® CRM-HTB-26™, www.atcc.org, (Ikediobi, Davies et al. 2006)). This 
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different location of the KRAS mutation on the MDA-MB-231 indicates that the DNAzyme 
designed to cleave the KRAS mRNA would not be effective. This result was confirmed in the 
results shown in Figure 3.7, where all samples had showed viability, even those treated with 
KRAS-DNAzyme and UV light.   
 
 
Figure 3.7. Results from control treatments of MCF-7 and MDA-MB-231 cells for 5 days using a 
flow cytometry assay. Lane 1: positive control live cells; Lane 2: negative control dead cells; 
Lane 3: 12 J/cm
2
 UV dosage; Lane 4: SNP-TAMRA DNAzyme construct dosage (1x, 5µl), 12 
J/cm
2
 UV, and 1.5µM Doxorubicin dosage; Lane 5: SNP-TAMRA DNAzyme construct dosage 
(1x, 5µl),12 J/cm
2
 UV, and 3µM Doxorubicin dosage; Lane 6: 1.5 µM Doxorubicin dosage; 
Lane 7: 3 µM Doxorubicin dosage; Lane 8: SNP-TAMRA DNAzyme construct dosage (1x, 5µl) 
and 1.5µM Doxorubicin dosage. DNAzyme concentration of sample from Lanes 4, 5, and 8 was 
0.13µg/100µl. 
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3.4 CONCLUSIONS 
The goals of this portion of the project include the determination of cellular thresholds to 
photoactivating doses of UV light, doxorubicin dose-response thresholds, cellular responses to 
treatment with DNAzyme alone and with synergistic doses of DNAzyme, UV, and doxorubicin.  
The system of cells used for proof of concept was crucial to show the actual effect of the 
treatment in comparison to the negative control. Three sets of cells were analyzed using either 
the flow cytometry assay, MTS assay, Alamar Blue assay, or a combination of these methods.  In 
each group, three cell lines were used. The group included one cell line containing the wild type 
KRAS gene, one cell line containing the mutant KRAS gene, and one cell line not containing 
either wild type or mutant KRAS gene. 
Cell “Set 1” included the negative control wild type KRAS line (HT29), the mutant 
KRAS line (SW620), and the negative control line (3T3). A large dose (5 µg, 8.3 mM) of KRAS 
DNAzyme showed no response in the SW620 colon cancer cells or 3T3 control fibroblast cells 
after 16 hours. Results from HT29 cells treated with the these DNAzyme concentration were not 
deemed reliable since the positive control live cells showed low viability.  Thus the decision was 
made to evaluate the constructs in different cells, termed “Set 2”, which included the negative 
control wild type KRAS line (HEK293), the mutant KRAS line (SW480), and the negative 
control line (3T3).  
There were several experiments testing the effective dosage of DNAzyme given to cells 
after 16 hours, the effective dosage of UV given to cells after 24 hours, and the effective dosage 
of Doxorubicin given to cells after 48 hours. However, the full synergistic effect of all 
components could not be compared until all cells and their controls went through the 5 day 
experimental protocol. Cells were seeded on Day 0. A treatment of SNP, DNAzyme, or SNP-
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DNAzyme conjugate is delivered on Day 1 (after 16 hours). Cells were treated with UV light on 
Day 2 (after 24 hours). Doxorubicin was delivered on Day 3 (after 48 hours). The treatment time 
for oligonucleotide construct delivery and UV dosage was determined from the method reported 
by Brown et al.(Brown, Qureshi et al. 2013). The treatment time for Doxorubicin delivery was 
determined from the method reported by Yu et al.(Yu, Wang et al. 2009). After the 5 day 
process, positive results would show the death of SW480 cells, tolerable amount of mortality of 
HEK293 cells, and viable negative control 3T3 cells. 
The effective dosage of UV given to cells after 24 hours was 12 J/cm
2
 (optimized dosage 
data not shown). The effective dosage of Doxorubicin given to cells after 48 hours was 1 µM 
Doxorubicin (optimized dosage data not shown).  Figure 3.4 lanes 7-10 show the SW480 colon 
cancer cells treated with SNP-DNAzyme construct, photoexposed, and doxorubicin treated were 
less viable than the SW480 colon cancer cells treated with SNP-DNAzyme construct and 
doxorubicin but not photoexposed. These results were encouraging; however, Figure 3.4 lane 4 
shows the SW480 colon cancer cells photoexposed with 12 J/cm2 UV were not highly viable, 
which varies significantly from results previously shown. Since one of the negative controls 
showed inconclusive results, definitive conclusions were not able to be made.   
Since one of the objectives of this project was to confer greater protection of the SNP-
tethered oligonucleotides from endonucleases, the SNP-DNAzyme constructs were backfilled 
with 11-Mercaptoundecanoic acid.  A comparison of backfilled and not backfilled samples that 
were and were not photoexposed was the focus of Figure 3.5. Again, these results are promising 
since the treatment quantitatively has a significant difference to the non-photoexposed samples in 
both the backfilled and non-backfilled samples. However, Figure 3.5 lane 4 shows the SW480 
colon cancer cells photoexposed with 12 J/cm2 UV were not highly viable. This varies 
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significantly from results previously shown. Since one of the negative controls is showing 
inconclusive results, it is hard to accept the reliability of the results. 
Since one of the objectives of this project was to establish an appropriate cell system to 
show the proof of concept of this drug-targeted gene therapy, it became crucial to check the 
viability of the controls using flow cytometry.  This experiment was an attempt to verify or to 
disqualify this system entirely. Figure 3.6 shows the data is unreliable when the dead control 
shows 100% viability with a 4,000 cell events count. After 5 days, the number of cells should be 
much larger than 50,000 cells. However, the cells were tough to kill and then collect to show a 
proper dead control. 70% ethanol, 100% ethanol, and hydrogen peroxide were used at different 
times to treat the dead control. In addition to having a difficult time collecting cells for the dead 
controls, data collected for the treated samples was also troublesome. Numbers of cell events 
collected varied significantly and could not be reliably trusted for accurate interpretations of 
treated samples’ effects. 
Cell set 3 included the negative control wild type RAS line (MCF-7) and the mutant 
KRAS line (MDA-MB-231)(Ikediobi, Davies et al. 2006, Adams, Deremer et al. 2010).  This set 
of cells was used because it contains a KRAS mutation. However, MDA-MB-231 cells contain 
the KRAS mutant gene on the 13
th
 codon instead of on the 12
th
 codon similar to the mutation in 
the SW480 and SW620 cells (ATCC® CRM-HTB-26™, www.atcc.org, (Ikediobi, Davies et al. 
2006). This means the DNAzyme designed to cleave the KRAS mRNA will not be effective. 
Figure 3.7 is proof since all treated samples had high viability. In Chapter 3, the construction of a 
SNP-10-23 DNAzyme oligonucleotide conjugate is significant in several regards to current 
developments in photoactivated gene regulation.  Thus, a photoactivated DNAzyme 
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oligonucleotide that could be easily delivered to cells via SNP transport, and then activated 
spatiotemporally has not been demonstrated in an appropriate cell system.   
The construction of the SNP-10-23 DNAzyme oligonucleotide conjugate is significant in 
several regards to current developments in photoactivated gene regulation. A photoactivated 
DNAzyme oligonucleotide that could be easily delivered to cells via SNP transport, and then 
activated spatiotemporally has not been demonstrated in an appropriate cell system.  The two 
objectives shown in this paper include increased protection of the SNP-DNAzyme construct, and 
establishment of a proper model showing the accurate effects of the treatment on cells.  The 
backfilled SNP-DNAzyme constructs were shown through characterization in Chapter 2 to be 
more packed together and DNAzymes were better protected from endonucleases, however their 
major impact in treatment could not be established since an appropriate model of cells could not 
be chosen. 
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CHAPTER 4. CONCLUSION AND FUTURE WORK 
4.1 CONCLUSION 
This project explored a gene-regulated chemotherapy using a silver nanoparticle (SNP) 
conjugated with DNAzyme oligonucleotides that target the mutant K-RAS gene to sensitize 
cancer cells to doxorubicin treatment.  UV light exposure to the conjugates disengages the 
oligonucleotides and permits DNAzyme-mediated cleavage of K-RAS mRNA.  As such these 
conjugates offer a targeted chemotherapeutic which could offer spatiotemporal specificity in 
killing only those cells with a mutant gene and in the intended therapeutic region of a patient.  
The goals of this project were to propose a nanoscale oligonucleotide delivery system that is 
designed to overcome known hurdles of nuclease protection and cellular delivery in 
chemotherapeutic applications. 
In the first portion of the project, detailed in Chapter 2, characterization of the stability 
and activity of citrate and HPC silver nanoparticle drug delivery systems constructed for the 
release of a photolabile DNA oligonucleotide were tested to show the improvement of temporal 
and spatial control efficiency of the designed construct.  The drug delivery vehicle, a ~60nm 
silver nanoparticle, is functionalized with a thiol-modified 10-23 DNAzyme oligonucleotide with 
an internal nitrobenzyl photocleavable linker.  The intended target for hybridization and gene 
silencing control is K-RAS mRNA.  The internal photocleavable linker permits spatiotemporal 
control release of the gene silencing K-RAS 10-23 DNAzyme oligonucleotides.   
The construction of a SNP-10-23 DNAzyme oligonucleotide conjugate is significant in 
several regards to current developments in photoactivated gene regulation. An inducible 
DNAzyme oligonucleotide that could be delivered to cells via SNP transport by stable and 
consistent particles is the critical point made by this project’s goals. While citrate-stabilized SNP 
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were first utilized in the project, hydroxypropylcellulose (HPC)-stabilized particles were chosen 
for future cell studies since they were highly biocompatible, aggregated less than the citrate 
SNPs, and were more shelf-stable. Gel electrophoresis was used to demonstrate effective 
cleavage activity in the various forms of the KRAS DNAzyme, which included thiol, 
photocleavable linker, and TAMRA modified forms, all showing similar degradation of RNA 
similar to the original unmodified DNAzyme.  Similarly, gel electrophoresis was used to show 
that DNAzyme tethered to the SNP showed less activity than when photoreleased from the 
conjugate.  DNAse did not digest SNP-tethered DNAzymes as quickly as DNAzymes free in 
solution, indicating protection of the nucleic acids in the conjugated form. 
The next directions of the project involved photoactivation evaluation of the construct in 
cells, hypothesized to sensitize mutant KRAS positive cells to chemotherapeutic, yet not 
affecting non-mutant containing KRAS cells. An aim motivating the use of this SNP construct is 
to cause less collateral damage due to off-target effects of medicines in unintended tissues. This 
gene-regulated approach could improve current chemotherapy efficacy, allowing use of lower 
concentrations of drug and thereby improving patient tolerance as well as targeted cancer cell 
necrosis. 
In the second portion of the project, detailed in Chapter 3, the goals of this portion of the 
project include the determination of cellular thresholds to photoactivating doses of UV light, 
doxorubicin dose-response thresholds, cellular responses to treatment with DNAzyme alone and 
with synergistic doses of DNAzyme, UV, and doxorubicin.  The system of cells used for proof of 
concept was crucial to show the actual effect of the treatment in comparison to the negative 
control. Three sets of cells were analyzed using either the flow cytometry assay, MTS assay, 
Alamar Blue assay, or a combination of these methods.  In each group, three cell lines were used. 
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The group included one cell line containing the wild type KRAS gene, one cell line containing 
the mutant KRAS gene, and one cell line not containing either wild type or mutant KRAS gene. 
A large dose (5 µg, 8.3 mM) of KRAS DNAzyme showed no response in Cell “Set 1”,  
thus the decision was made to evaluate the constructs in different cells, termed “Set 2”, which 
included the negative control wild type KRAS line (HEK293), the mutant KRAS line (SW480), 
and the negative control line (3T3).  Several experiments testing the effective dosage of 
DNAzyme given to cells after 16 hours, the effective dosage of UV given to cells after 24 hours, 
and the effective dosage of Doxorubicin given to cells after 48 hours were performed. 
The full synergistic effect of all components could not be compared until all cells and 
their controls went through the 5 day experimental protocol. Cells were seeded on Day 0. A 
treatment of SNP, DNAzyme, or SNP-DNAzyme conjugate is delivered on Day 1 (after 16 
hours). Cells were treated with UV light on Day 2 (after 24 hours). Doxorubicin was delivered 
on Day 3 (after 48 hours). The treatment time for oligonucleotide construct delivery and UV 
dosage was determined from the method reported by Brown et al.(Brown, Qureshi et al. 2013). 
The treatment time for Doxorubicin delivery was determined from the method reported by Yu et 
al.(Yu, Wang et al. 2009). After the 5 day process, positive results would show the death of 
SW480 cells, tolerable amount of mortality of HEK293 cells, and viable negative control 3T3 
cells. 
The effective dosage of UV given to cells after 24 hours was 12 J/cm
2
 (optimized dosage 
data not shown). The effective dosage of Doxorubicin given to cells after 48 hours was 1 µM 
Doxorubicin (optimized dosage data not shown).  SW480 colon cancer cells treated with SNP-
DNAzyme construct, photoexposed, and doxorubicin treated were less viable than the SW480 
colon cancer cells treated with SNP-DNAzyme construct and doxorubicin but not photoexposed. 
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However, in a later experiment, SW480 colon cancer cells photoexposed with 12 J/cm2 UV were 
not highly viable. The SNP-DNAzyme constructs were backfilled with 11-Mercaptoundecanoic 
acid was to confer greater protection of the SNP-tethered oligonucleotides from endonucleases.  
The treatment showed a quantitative difference to the non-photoexposed samples in both the 
backfilled and non-backfilled samples. However, SW480 colon cancer cells photoexposed with 
12 J/cm2 UV were not highly viable. Since one of the negative controls is showing inconclusive 
results, it is hard to accept the reliability of the results. 
An appropriate cell system was needed to show the proof of concept of this drug-targeted 
gene therapy.  Flow cytometry was used to check the viability of the controls.  This experiment 
was an attempt to verify or to disqualify this system entirely.  Flow data was unreliable since the 
dead control showed 100% viability with a 4,000 cell events count. After 5 days, the number of 
cells should be much larger than 50,000 cells. However, the cells were tough to kill and then 
collect to show a proper dead control. 70% ethanol, 100% ethanol, and hydrogen peroxide were 
used at different times to treat the dead control. In addition to having a difficult time collecting 
cells for the dead controls, data collected for the treated samples was also troublesome. Numbers 
of cell events collected varied significantly and could not be reliably trusted for accurate 
interpretations of treated samples’ effects. 
Cell “set 3” included the negative control wild type RAS line (MCF-7) and the mutant 
KRAS line (MDA-MB-231)(Ikediobi, Davies et al. 2006, Adams, Deremer et al. 2010).  
However, MDA-MB-231 cells contain the KRAS mutant gene on the 13
th
 codon instead of on 
the 12
th
 codon similar to the mutation in the SW480 and SW620 cells (ATCC® CRM-HTB-
26™, www.atcc.org, (Ikediobi, Davies et al. 2006). This means the DNAzyme designed to 
cleave the KRAS mRNA will not be effective.  
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The construction of the SNP-10-23 DNAzyme oligonucleotide conjugate is significant in 
several regards to current developments in photoactivated gene regulation. A photoactivated 
DNAzyme oligonucleotide that could be easily delivered to cells via SNP transport, and then 
activated spatiotemporally has not been demonstrated in an appropriate cell system.  The two 
objectives shown in this project include increased protection of the SNP-DNAzyme construct, 
and establishment of a proper model showing the accurate effects of the treatment on cells.  The 
backfilled SNP-DNAzyme constructs were shown through characterization in Chapter 2 to be 
more densely packed, with  DNAzymes better protected from endonucleases, however their 
major impact in treatment could not be established since an appropriate model of cells could not 
be chosen. 
4.2 FUTURE WORK  
This project has demonstrated a promising proof of concept of cleavage of a targeted 
mRNA using complementary DNAzyme, cell delivery using the HPC SNPs, and packing of 
DNAzyme on the HPC SNPs backfilling with 11-mercaptoundecanoic acid.  DNAzyme 
oligonucleotides conjugated to the surface of SNP via thiol-metal linkages are thought to pack 
densely(Qureshi, Monroe et al. 2013), thus protecting them from enzymatic degradation.  
Johnson et al. reported 11-mercaptoundecanoic acid aided the homogeneous dispersal of silver 
nanoparticles (Johnson Jr, Kang et al. 2008)  addressing an important need for reduced 
aggregation to aid in a greater packing density for this project.  By using this more successful 
packing method, future work will specifically focus on finding cell lines to test the enhanced 
DNAzyme construct and to find a more sensitive assay to test for cell viability. 
The DNA construct includes a photocleavable nitrobenzyl group to permit 
oligonucleotide release from the SNP with UV light exposure. The SNP-DNAzyme construct 
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was designed to be evaluated in a system requiring targeted gene silencing, whereby precise light 
exposure offers spatiotemporal control. However, there is a great need for an appropriate cell line 
to prove the synergistic effect of the spatialtemporal control of the released DNAzyme and 
Doxorubicin in vitro.  Thus, new cell lines were sought after that included the KRAS mutant 
gene.  Haraguchi et al. reported the identification and characterization of side populations of 
cancer cells that act similarly to stem cells(Haraguchi, Utsunomiya et al. 2006).    Specifically, 
the cells have regenerative properties.  However, the SW480s can generate side populations of 
cancer cells and non-side populations of cancer cells.  For future use, the project could be moved 
forward using the side population of SW480 cancer cells since they are a hardier cell line 
preconditioned through generations of side passages in culture. The hardier cell line which would 
ideally be robust enough for the 5 day experiment protocol, remain through sample processing, 
and show better dynamic range between positive and negative control responses in the viability 
assays may be worth evaluation. Haraguchi et al. also were successful in dosing HuH7 side 
population and non-side population cells with doxorubicin; thus these lines may also warrant 
exploration.   
   Instead of using an alamar blue assay or MTT assay, Haraguchi et al. used the 
CellTiter-Glo luminescent cell viability assay from Promega (Hannah, Beck et al. 2001, 
Haraguchi, Utsunomiya et al. 2006) to evaluate doxorubicin-induced cell death.  Petty et al. 
report that ATP-based assays have greater sensitivity distinguishing viability with lower numbers 
of cells than MTT (Petty, Sutherland et al. 1995).  These sensitive ATP-based assays are an 
excellent future option for viability since they do not require trypsination as do the flow 
cytometry assays; thus cells will be counted and they will not deteriorate during processing. 
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This project has significance because it addresses the need to develop effective means of 
delivering therapeutic oligonucleotides to targeted cells with high efficiency and precision. 
Another suggestion for the future directions of this project is to address that high efficiency and 
precision targeting by using tumors from metastatic colorectal cancer patients with the KRAS 
mutant gene in the 12th codon to test.  Lièvre et al. reported the effectiveness of Cetuximab 
therapy in 30  tumors from metastatic colorectal cancer patients(Lievre, Bachet et al. 2006).  Ex 
vivo tumor tissue samples from patients could be tested as an alternative to the immortalized cell 
lines. 
Future directions also include comparison of DNAzyme activity between direct-caged 
DNAzyme oligonucleotides and the SNP-DNAzyme constructs used in this project.  The 
packaging of the delivery method could be redesigned and characterized for most effective 
delivery within cells since one of the main goals has been to produce less collateral damage due 
to off-target effects of medicines released in unintended tissues.   
Overall, several changes can be tried to change this proof of concept idea into an 
effective gene-regulated therapy.  Truly, the ultimate end point is to improve current patient 
therapy.  With possibly the use of one of these new suggestions, the project can begin the start of 
a new therapy regimen which allows patients one more option in their medical choices.    
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APPENDIX A. PROTOCOLS 
 
Note: The protocols listed in this section are proposed methods used in the Monroe lab including 
ones passed down from previous graduate students and student undergraduate workers. They 
represent the most updated versions at the time of the distribution of this thesis. All procedures 
can be changed for successful completion of an individual project. 
A1. Cell Culture: Cell Splitting and Seeding Procedure 
A. Feeding 
1. Aspirate Media 
2. Add 5 ml of fresh media per T-25 flask (doubling time = 24 hours) 
3. Feed once a week for T-25 flask 
B. Splitting Cells  
1. Aspirate media from flask to waste 
2. Rinse w/ 5 ml D-PBS (Ca+ & Mg+ free) and swivel in flask 
3. Aspirate off D-PBS to waste 
4. Add 5ml of Trypsin solution 
a. Wait ~10 min for cells to come off dish at room temperature. Gently rock flask 
periodically and observe under microscope to make sure the cells are detaching 
5. Add 5 ml of media to inactivate trypsin 
6. Transfer suspension to a 50 ml centrifuge tube 
7. Spin down the cells at 1800rpm for 5 min on the centrifuge (Eppendorf 5702) 
8. Decant supernatant 
9. Resuspend in 5ml of media 
a. For passaging: 
i. Add 5ml fresh media to a new T-25 flask 
ii. Add 3-5 drops of the cell suspension in the new T-25 flask for the flask 
passaging 
b. For experiment: 
c. Dilute cell media (1 ml into 9 ml fresh media) and seed 500 ul diluted cell 
solution into 8-well chambered wells (LabTek Chambered Slides, NUNC) 
A2. Transfection  
A. Transfection Protocol 
1. Add TrojanPorter to 100ul of SFM (serum-free media) and incubate for 5 min at RT 
2. Complex DNA & TrojanPorter for ~15 min at RT 
3. Add polyplexes directly to 500 ul of cell media in 8-well chambers, transfect for 16-24 
hrs 
B. Transfection of SNP-oligo complexes: 
1. Concentrate final purified SNP-oligo sample (10x) 
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2. Add 5-10ul of 5x SNP-oligo concentrate (50pM concentration) per well in 8-well 
confocal microscopy chambered slide (500 ul total volume cell media – 0.8 cm2/well of 
culture area)  
3. Final amount of oligo added is approximated at 2ug for 5ul of 5x SNP-oligo concentrate 
(1000:1 oligo to particle ratio) 
A3. Nuclease Digestion Assay 
A) Nuclease Assay for SNP-oligo conjugates 
1. Purify SNP-oligo conjugates and resuspend in DNase I NEB Buffer 
2. Prepare TYE-oligo solution in DNase I buffer (3 samples) 
3. Add DNase I to sample solutions – incubate at 37°C for digestion intervals 
4. Add STOP buffer (EDTA) to inactive DNase I 
5. Purify digested SNP-oligo conjugates (1x) 
6. DTT-remove oligo dorm SNP-oligo conjugates 
7. Amicon filter TYE-oligo samples to remove salt and reduce volume for gel 
A4. SNP Synthesis  
A) Citrate SNP Synthesis 
1. Thorough cleaning of all glassware with ethanol 
2. Add .09g silver nitrate to 500ml DI water in large beaker 
3. Add .3g sodium citrate (1%) ro 30ml DI water in small beaker 
4. Bring silver nitrate to a boil while stirring (95°C) 
5. Add 10ml of 1% citrate at a rate of 0.5ml/min (drop wise) 
6. Color will change eat 2ml of added citrate (pale yellow) 
7. Color will change at 5ml of added citrate (dark green) 
8. Let solution boil 10 min after addition of 10ml citrate 
9. Cool solution to RT and quickly transfer to fridge in airtight, dark conditions 
A5. SNP Functionalization  
A) 4500: 1 oligo to nanoparticles ratio; 1ml 72 pM colloid=7.2x1014mol nanoparticles; 0.324 
uM Oligo per 1ml silver colloid 
B) Protocol 
1. Add Thiol-modified or cyclic-disulfide-modified oligonucleotides to citrate-stabilized 
silver nanoparticles (~ .324 nmoles oligonucleotide per 1ml of 72 pM colloid) 
2. After 3hrs, add 10ul of 10% SDS, 25ul phosphate buffer (0.1 M; pH=7.4) to bring the 
mixture to 0.0025 M phosphate 
3. After 12 hrs begin salt aging process: in 4 hr intervals add 10ul aliquots of Tris-NaCl 
buffer (2M in DI water, pH=8-8.5) to a final concentration of 160-200 mM Tris-NaCl (8-
10 additions of 10ul aliquots) or until conjugate colloid is fading due to functionalization 
(to lighter golden color) 
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4. Rock resulting mixture gently (lowest speed) over course of 48 hrs 
5. Purification via centrifugation (3x 7000RPM) 
6. Pull supernatant off SNP pellet and resuspend in dilute (100mM) Tris-NaCl Buffer + 
10% SDS 
7. Purify particles with centrifugation 3X 20min @ 7,000rpm 
8. Backfill SNPs with 1/10 DNAzyme concentration of 11-Mercaptoundecanoic acid for 2 
hrs 
9. Purify particles with centrifugation 3X 20min @ 7,000rpm. Samples are ready. 
A6. Flash Photolysis Using Gel Box 
 
1. Warm up UV lamp for thirty minutes prior to flashing 
2. Transfer ½ of each reaction solution to a 0.2ml PCR tube 
3. Place samples under the UV lamp for 30mins (caged solutions should turn yellow) 
4. Samples can be analyzed, purified, or placed in an assay at this point. 
A7. Gel Electrophoresis  
 
Materials 
Mini-PROTEAN 3 System (Bio-Rad) 
Precast 5% and 15% polyacrylamide (Bio-Rad) 
10X TBE buffer (Bio-Rad) 
Syber Gold™ stain 10,000X (Molecular Probes) 
Procedure 
1. Prepare samples and markers with appropriate dyes. 
2. Remove gel from sleeve and record all pertinent information. 
3. Using a razor blade, cut the plastic coating along the line at the bottom of the gel. 
4. Peel the released strip of plastic exposing the gel. 
5. Mount the gel cassette into the Mini-PROTEAN 3 System. 
• Position the wells to face the inner chamber. 
• Hold the cassette down firmly and close both clamps simultaneously. 
6. Load the inner chamber above the wells with 1X TBE buffer. 
7. Remove the well comb. 
8. Wait 5 minutes to ensure a proper seal has been formed. 
9. Flush each well several times with excess TBE buffer. 
10. Load the outer chamber above the expose gel with 1X TBE buffer. 
11. Load each sample into its specified well. 
12. Connect the lid ensuring proper electrode connections (color coded). 
13. Set the voltage and the timer settings as desired (do not exceed 75 Volts). 
14. Press run. 
15. Periodically inspect that the system is running properly. 
16. When completed, remove the gel from the plastic casing. 
17. Stain with Syber Gold™ at 1X (gently rock for 20 minutes). 
18. Rinse the gel with distilled water. 
19. Perform a UV visualization of the gel under several exposure times 
20. Clean all surfaces and dispose of the gel and all consumables. 
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21. Treat all potentially Syber Gold™ contaminated materials as hazardous waste.  
 
A8. Typhoon 9410 Variable Mode Imager 
 
1. Samples were visualized on a Typhoon 9410 Variable Mode Imager (normal sensitivity, 400 
PMT Volts, prescan at 1000 microns pixel size, imaging at 100 microns pixel size) (GE 
Healthcare, Piscataway, NJ).  
2. 488nm laser line was used to image gels stained with SYBR Gold using the 540bp30 filter.  
3. 633 nm laser line was used to image gels with RNA containing TYE665 (648/666)  using the 
670bp30 filter.    
A9.  Flash Photolysis Using GreenSpot 
1. Warm up GreenSpot UV lamp for thirty minutes prior to flashing 
2. Transfer appropriate amount of each reaction solution to a 96, 48, or 12 well plate 
3. Place samples under the GreenSpot UV lamp assembly with 3cm from fiber to bottom of plate 
allowing for a 12 J/cm
2
 dosage 
4. Samples can be analyzed, purified, further treated, or placed in an assay at this point. 
A10.  MTS Assay 
 
A. MTS Cell Proliferation Assay Protocol for Cells in 96-well plates 
Required Materials: CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) 
was purchased from Promega
 
(Madison, WI).   
 
1. Seed cells into 96-well plate at desired density. (See cell count optimization sheet for 
instructions on counting cells and optimizing plate-reader signal. Aim for a plate reader 
readout of 0.75-1.25.) Remember to leave wells blank (but filled with DMEM) for control 
groups.   
2. If you wish to have a dead control group.  
a. Empty DMEM from wells, pipette 30uL of 2% H2O2 or paraformaldahyde (PFA). 
Incubate for 20 minutes.  
b. Empty PFA from wells. H2O2 removes cells from the plate surface while PFA adheres 
them. Therefore removing H2O2 will remove dead cells as well. Small amount of 
remnant H2O2  will not interfere with the assay. 
c. Add 100uL DMEM to emptied wells. This is necessary because the MTS assay reacts 
with DMEM to produce color change effect. If you are imaging cells in PBS or the 
buffer, remove them and replace with DMEM before conducting MTS assay. 
3. Retrieve cells from incubator, and add 20uL 20:1 MTS/PMS solution to all wells (including 
blank control wells) under sterile hood. 
4. Incubate the cells for 4 hours. 
5. Retrieve cells from incubator and check for a purple precipitate that should form inside cells.  
6. Measure the absorbance of each well at 490 nm on the plate reader in room 112. Remember 
to bring a flash drive. 
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a. Turn on plate reader, then computer. Password to the computer is molly02. 
b. Make sure that you are using a 490nm filter. 
c. Click on the “Wallac” plate reader icon on the desktop. For first users, a new test 
must be created.  
i. To create new test. 
1. Go to “tools” menu, click on explorer.  
2. Create a new folder by right clicking. 
3. Create a new test inside your folder by right clicking. 
ii. To run test: 
1. Go to “tools” menu, click on start wizard. Follow the instructions and 
choose the test you wish to use. 
d. Export data: 
i. In “Tools” menu, click “explorer.” This will take you to a database of all your 
recorded results.  
ii. Click on the one you wish to export. When the file opens, go to the left most 
menu, and click “export.” 
e. Turn off the computer, then the plate reader. 
A11.  Alamar Blue Assay  
A. Alamar Blue® Cell Viability Assay Protocol for Cells in 96-well plates 
Required Materials: Alamar Blue® Cell Viability Reagent was purchased from Invitrogen
TM
 by 
Thermo Fisher Scientific (Rochester, NY).   
 
1. Seed cells into 96-well plate at desired density. (See cell count optimization sheet for 
instructions on counting cells and optimizing plate-reader signal. Aim for a plate reader 
readout of 0.75-1.25.) Remember to leave wells blank (but filled with DMEM) for control 
groups.   
2. If you wish to have a dead control group.  
a. Empty DMEM from wells, pipette 30uL of 2% H2O2 or paraformaldahyde (PFA). 
Incubate for 20 minutes.  
b. Empty PFA from wells. H2O2 removes cells from the plate surface while PFA adheres 
them. Therefore removing H2O2 will remove dead cells as well. Small amount of 
remnant H2O2  will not interfere with the assay. 
c. Add 100uL DMEM to emptied wells. This is necessary because the MTS assay reacts 
with DMEM to produce color change effect. If you are imaging cells in PBS or the 
buffer, remove them and replace with DMEM before conducting Alamar Blue assay. 
3. Retrieve cells from incubator, and add 100µl of pooled 10:1 corresponding media/ 
alamarBlue® dye  solution to all wells (including blank control wells) under sterile hood. 
4. Incubate the cells for 4 hours. 
5. Retrieve cells from incubator and check for a color change.  
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6. Measure the fluorescence of each well at excitation and emission 531nm/ 595nm on the plate 
reader in room 112. Remember to bring a flash drive. 
a. Turn on plate reader, then computer. Password to the computer is molly02. 
b. Make sure that you are using an appropriate filter. 
c. Click on the “Wallac” plate reader icon on the desktop. For first users, a new test 
must be created.  
i. To create new test. 
1. Go to “tools” menu, click on explorer.  
2. Create a new folder by right clicking. 
3. Create a new test inside your folder by right clicking. 
ii. To run test: 
1. Go to “tools” menu, click on start wizard. Follow the instructions and 
choose the test you wish to use. 
d. Export data: 
i. In “Tools” menu, click “explorer.” This will take you to a database of all your 
recorded results.  
ii. Click on the one you wish to export. When the file opens, go to the left most 
menu, and click “export.” 
e. Turn off the computer, then the plate reader. 
A12. Flow Cytometry Assay 
A. Flow Cytometry Assay Protocol for Cells in 12-well plates 
Required Materials: Sytox® Red dead cell stain was purchased from Molecular Probes
TM
 by 
Thermo Fisher Scientific (Rochester, NY).   
 
1. Seed cells into 12-well plate at desired density.  
2. If you wish to have a dead control group.  
a. Empty DMEM from wells, pipette 30uL of 2% H2O2 or paraformaldahyde (PFA). 
Incubate for 20 minutes.  
b. Empty PFA from wells. H2O2 removes cells from the plate surface while PFA adheres 
them. Therefore removing H2O2 will remove dead cells as well. Small amount of 
remnant H2O2  will not interfere with the assay. 
3. After treatment, wash non-adhered cells with 1 ml D-PBS and collect. 
4. Harvest adhered cells by trypsinization (0.25% Trypsin) for 10 minutes.  
5. Pool cells together and centrifuge at 1800 rpm for 5 minutes to obtain cell pellet.  
6. Re-suspend cells in 1 ml D-PBS and stain with ending concentration of 5nM Sytox Red for 
15 minutes in the dark. 
7. Centrifuge and fix pellet  in 250 ul of 1% paraformaldehyde (PFA) solution in D-PBS  
8. Bring samples to Ms. Marilyn for flow cytometric analysis of viability with a BD FACS 
Calibur cytometer (Franklin Lakes, NJ). 
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9.  For each sample, scatter and fluorescent data are collected for 30,000 cell events using 
Cellquest pro (BD Biosciences, San Jose, CA) and further analyzed using WinMDI 2.8 
software (by Dr M Dietrich, LSUHSC Veterinary School, Baton Rouge, LA). 
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